The Biosynthesis of Enzymatically Oxidized Lipids

Ali A. Hajeyah1*, William J. Griffiths2, Yuqin Wang2, Andrew J. Finch3 and Valerie B. O’Donnell1

1 Systems Immunity Research Institute and Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, 2 Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom, 3 Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Enzymatically oxidized lipids are a specific group of biomolecules that function as key signaling mediators and hormones, regulating various cellular and physiological processes from metabolism and cell death to inflammation and the immune response. They are broadly categorized as either polyunsaturated fatty acid (PUFA) containing (free acid oxygenated PUFA “oxylipins”, endocannabinoids, oxidized phospholipids) or cholesterol derivatives (oxysterols, steroid hormones, and bile acids). Their biosynthesis is accomplished by families of enzymes that include lipoxygenases (LOX), cyclooxygenases (COX), cytochrome P450s (CYP), and aldo-keto reductases (AKR). In contrast, non-enzymatically oxidized lipids are produced by uncontrolled oxidation and are broadly considered to be harmful. Here, we provide an overview of the biochemistry and enzymology of LOXs, COXs, CYPs, and AKRs in humans. Next, we present biosynthetic pathways for oxylipins, oxidized phospholipids, oxysterols, bile acids and steroid hormones. Last, we address gaps in knowledge and suggest directions for future work.

Keywords: biosynthesis of oxidized lipids, lipoxygenase (LOX), cyclooxygenase (COX), cytochrome P450, aldo-keto reductase (AKR), oxylipins, oxidized phospholipids, sterols and steroid hormones

INTRODUCTION

Lipids are a key component of life. They play essential roles in membrane structure, cell signaling and energy production. Like other biomolecules, they undergo chemical modifications that expand their functional repertoire. One modification that has been steadily gaining attention is lipid oxygenation, with interest being attributed to two factors: advances in analytical methods that allow detection of oxygenated species, and the ever-growing body of literature implicating them in biological processes and disease. “Enzymatically oxidized lipids” constitute a large portion of known oxygenated lipid mediators, being bioactive lipids that are produced locally through specific pathways.

Abbreviations: 4-HNE, 4-hydroxy-2-nonenal; AA, arachidonic acid; AKR, aldo-keto reductase; ALA, α-linolenic acid; COX, cyclooxygenase; CE, cholesteryl ester; CYP, cytochrome P450; DGLA, dihomo-γ-linolenic acid; DHA, docosahexaenoic acid; DPEP2, dipetidase 2; EET, epoxy-eicosatetraenoic acid; EPA, eicosapentaenoic acid; GGT, γ-glutamyl transpeptidase; GLA, γ-linolenic acid; GPCR, G protein-coupled receptor; HETE, hydroxy-eicosatetraenoic acid; HpETE, hydroperoxy-eicosatetraenoic acid; HSD, hydroxysteroid dehydrogenase; LA, linoleic acid; LOX, lipoxygenase; LTA4, leukotriene A4; lysoPL, lysophospholipid; oxPL, oxidized phospholipids; PG, prostaglandin; PL, phospholipid; PUFA, polyunsaturated fatty acid; SDR, short-chain dehydrogenase/reductase; SPM, specialized pro-resolving mediator.
biosynthetic pathways in response to extracellular stimuli. Those derived from oxygenation of polyunsaturated fatty acids (PUFA) such as arachidonic acid (AA) include prostaglandins (PG), thromboxanes and leukotrienes, which function in modulating inflammation, the immune response, and hemostasis, and are broadly termed “oxylipins” (1, 2). Oxylipins also include multiply oxygenated derivatives of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), of which specific enantiomers have been termed “specialized pro-resolving mediators” (SPM) for their proposed roles in the resolution of inflammation (3). SPMs derived from DHA include D-resolvins, maresins and protectin. On the other hand, E-resolvins are proposed to be generated from EPA but the enzymatic pathways are unclear and require further investigation. Oxylipins also constitute a core functional group on larger lipids including oxidized phospholipids (oxPL), endocannabinoids and cholesteryl esters (CE). Oxidized CE are conversely associated with atherosclerosis progression (4), whereas enzymatically oxidized phospholipids (eoxPL) are pro-coagulant and promote a variety of innate immune actions in leukocytes and platelets (5).

Enzymatically oxidized lipids are not limited to those containing oxygenated PUFA functional groups. Oxidized derivatives of cholesterol include steroid hormones, bile acids and their oxysterol precursors. Steroid hormones regulate multiple physiological processes including metabolism (e.g., glucose homeostasis by glucocorticoids), water retention, immune function, and development of sex characteristics (6–8). Bile acids, while traditionally known for aiding in fat digestion and bilirubin excretion, are also being increasingly revealed as signaling molecules and metabolic regulators (9, 10). Similarly, accumulating evidence is revealing oxysterols as more than just bile acid intermediates with functions in signaling (11).

Enzymatic lipid oxidation is facilitated by a network of proteins that use PUFA or sterols as substrates, specifically, lipoxygenase (LOX), cyclooxygenase (COX), and cytochrome P450 (CYP), all of which exist as several isoforms exhibiting broad substrate specificity (12–16). In general, PUFA oxygenation is initiated by COXs, LOXs, and to a lesser extent CYPs. For example, the biosynthesis of PGs is initiated by COXs, whereas the formation of leukotrienes begins with a LOX. Additionally, crossovers between COX, LOX, and CYP is proposed to produce various SPMs. On the other hand, cholesterol oxidation is dominated by CYPs. For example, sidechain shortening during steroid hormone synthesis is catalyzed by CYP11A1 (P450scc). Bile acids are synthesized from cholesterol predominantly by two pathways: the neutral pathway starting with an endoplasmic reticulum resident enzyme CYP7A1, and the acidic pathway starting with CYP27A1 in mitochondria (17). CYPs account for many enzymes in both pathways, catalyzing the formation of oxysterols as well as oxygenated PUFA. Last, aldoketo reductases (AKR) and hydroxysteroid dehydrogenases (HSD) catalyze key redox reactions in bile acid and steroid hormone biosynthesis.

By contrast, non-enzymatically oxidized lipids are produced through uncontrolled oxidation via free radical mechanisms. This involves the oxidation of lipids by free radicals, followed by chain propagation and ultimately termination. Notably, during oxygenation of PUFA, active site intermediates can escape to react in an uncontrolled manner, leading to some oxidized lipids forming due to non-enzymatic rearrangements of enzymatic pathway intermediates.

Here, we provide an overview of major enzymes involved in lipid metabolism, including LOXs, COXs, CYPs and AKRs. Then we outline the biosynthetic pathways of oxylipins, oxPLs, oxysterols, bile acids and steroid hormones. Finally, we address outstanding questions and suggest directions for future work.

**ENZYME FAMILIES INVOLVED IN THE BIOSYNTHESIS OF OXIDIZED LIPIDS**

**Lipoxygenase (LOX)**

**Human LOX: Isoforms and Tissue Distribution**

Lipoxygenases (LOX) are a family of non-heme iron-containing dioxygenases. They catalyze the stereospecific addition of dioxygen to lipids containing a (1Z,4Z)-pentadiene group producing lipid hydroperoxides. The human genome contains six functional LOX genes, expressed in various tissues (Table 1). LOXs were traditionally named according to their positional specificity for arachidonic acid (AA). However, the latest characterized member eLOX3 has limited lipoxygenase activity (38), while some LOXs show preference for other PUFA. Sequence analysis of human LOXs (using UniProt entries (39)) shows that 12R-LOX (Alox12b) is evolutionarily closer to 15-LOX-2 (Alox15b; 48.2% identity) than 12S-LOX (Alox12; 35.7% identity). Additionally, human 15-LOX-1 (Alox15) exhibits dual positional specificity which is not reflected in the name (18). The lack of a robust naming system is a common cause of confusion. Thus, the use of gene names alongside enzyme names is recommended (14).

LOXs are typically constitutively expressed, except for 15-LOX-1 (Alox15) which is inducible by IL-4 and IL-13 in monocyte-derived macrophages (28). Although 15-LOX-2 (Alox15b) is constitutively expressed in the same cell type, its expression can be increased by cytokines, hypoxia, and lipopolysaccharide. It is possible that other constitutively expressed LOXs share this property.

**Structure and Membrane Association of Mammalian LOXs**

There are a limited number of published crystal structures for mammalian LOXs. Available structures of 5- and 15-LOXs show a single polypeptide chain that consists of two domains: a small β-barrel N-terminal domain and a larger α-helix-rich C-terminal domain containing the catalytic non-heme iron (40–42). The coordination positions of the catalytic iron are occupied by three conserved His residues, the carboxyl group of the C-terminus Ile residue, a water molecule and one last variable ligand (water, His, Asn, or Ser). Studies on mammalian LOXs found that the N-terminal domain is not required for catalytic activity, but instead functions in membrane binding and regulation (43, 44). The N-terminal domain of mammalian 5-LOXs (Alox5) was found to be important for the calcium-dependent translocation from the
cytosol or nucleus (depending on cell type) to the nuclear envelope and enzyme activity (45, 46). Similar findings were reported for mammalian 15-LOXs, with the translocation from the cytosol to the cell membrane instead (47, 48). Unlike other reported for mammalian 15-LOXs, with the translocation from cytosol or nucleus (depending on cell type) to the nuclear envelope and enzyme activity (45, 46). Similar findings were reported for mammalian 15-LOXs, with the translocation from the cytosol to the cell membrane instead (47, 48). Unlike other 15-LOXs, the activity of 5-LOX requires interaction with partner proteins 5-lipoxygenase activating protein (FLAP), coactosin-like protein (CLP) and cytosolic phospholipase A2 (cPLA2) (49, 50). Additionally, 5-LOX undergoes phosphorylation at multiple sites, regulating its translocation and activity, and is allosterically activated by ATP (51–53).

On the other hand, 15-LOXs do not require accessory proteins for free FA oxygenation. Instead, 15-LOXs form a complex with a small scaffolding protein, phosphatidylyethanolamine-binding protein 1 (PEPB1) (54). This complex facilitates 15-LOX activity on PL-esterified PUFA and is proposed to play regulatory roles in ferroptosis along with GPX. PEPB1 has been suggested to direct 15-LOX activity toward PL substrates when free AA is depleted (55). The crystal structure of human 15-LOX-2 (ALOX15B) revealed a hydrophobic loop in the N-terminal domain that is flanked by calcium binding sites, a feature that is absent in 5-LOX (42). Hydrogen-deuterium exchange mass spectrometry showed a decrease in H/D exchange for the hydrophobic loop, supporting a role in membrane hopping (48, 56). Both 5-LOX and 15-LOXs associate with membranes in a calcium-dependent manner but they exhibit differences in activity, translocation and binding partners.

Calcium-dependent membrane association has also been shown for platelet 12S-LOX (ALOX12), and more recently, 12R-LOX (ALOX12B), and eLOX3 (19, 57). The activity of 12S-LOX (ALOX12) is thought to be regulated by the availability of its substrates, which are supplied through the action of phospholipases. It is currently unknown whether 12S-LOX is regulated by other mechanisms. Research on the regulation of 12R-LOX and eLOX3 is also limited, although calcium has been shown to increase the activity of mouse 12R-LOX but not eLOX3 (58).

Aside from the catalytic domain of 12S-LOX (ALOX12), no crystal structures are available for 12-LOXs or eLOX3. However, human platelet 12S-LOX (ALOX12) was characterized using small-angle x-ray scattering, showing its occurrence as a dimer in solution (59). This challenged the idea that all human LOXs exist and function as monomers. Human 5-LOX displays full activity as a monomer but forms functional dimers as well, thought to exist in equilibrium (60). Similarly, rabbit 15-LOX-1 (ALOX15) undergoes ligand-induced dimerization in aqueous solutions, and molecular dynamics predicts stable dimers in the presence of substrate fatty acids (61). This supports the idea of monomer-dimer equilibria in LOXs. Human 15-LOX-1 (81.1% sequence identity to rabbit) likely exhibits the same property.

In summary, all six human LOXs associate with membranes in a calcium-dependent manner. 5-LOX requires the help of protein partners for membrane translocation and activity, whereas 15-LOXs only require a partner protein to efficiently catalyze the oxygenation of PL-esterified PUFA. Less is known about the regulation of 12-LOXs and eLOX3. Dimerization and monomer-dimer equilibria have been observed in several LOX isoforms and represent a potential regulatory mechanism. Finally, complete crystal structures have yet to be reported for 12S-LOX, 12R-LOX, and eLOX3. In the case of 12S-LOX, a crystal structure would be beneficial in the rational design of inhibitors, as the enzyme functions in platelet activation.

### Reaction Mechanism of LOX

The dioxygenase activity of LOX represents a highly controlled form of lipid peroxidation (Figure 1A). First, stereospecific hydrogen atom removal is carried out by the non-heme ferric iron [Fe(III)]. Fe(III) is not a strong enough oxidizer to abstract hydrogen directly. Thus, a mechanism involving proton-coupled electron transfer (PCET) has been proposed (62) (Figure 1A). In this, the electron is directly transferred to Fe(III) and the proton is picked up by the hydroxide ligand in a concerted mechanism (simultaneously), producing a lipid alkyl radical and ferrous iron [Fe(II)]. This is followed by a rearrangement of the lipid radical into the more stable conjugated diene. After that, dioxygen is introduced onto the opposite side of the removed hydrogen (antarafacially), generating a lipid peroxyl radical. Finally, the lipid peroxyl radical is reduced by Fe(II) and protonated to form a lipid hydroperoxide, through PCET. This reforms Fe(III) for another round of catalysis.
FIGURE 1 | Reaction mechanism of lipoxygenases (LOXs). (A) Dioxygenase activity. Hydrogen atom removal is thought to proceed through a proton-coupled electron transfer mechanism (PCET), in which the transfer of electron and proton occur simultaneously (concerted mechanism), depicted separately for simplicity. (B) Lipohydroperoxidase activity. (C) Leukotriene synthase activity. (D) Activation of LOX by a hydroperoxide.
The stereo and regio-specificity of lipooxygenation are determined by structural features which: (i) accommodate and position the substrate in a specific orientation, and (ii) direct radical rearrangement and oxygen insertion. These features include a U-shaped cavity that accommodates the substrate (63), a migration channel for oxygen (64), a glycine/alanine “switch” that determines stereospecificity by directing oxygen (65), and several amino acid residues that control positional specificity (66, 67). These properties are explored in-depth by Newcomer and Brash (68).

In addition to classical dioxygenase activity, LOXs catalyze other reactions that involve free-radical processes like hydrogen abstraction, homolytic bond cleavage, and radical rearrangement (69). eLOX3 exhibits a hydroperoxide isomerase activity (lipohydroperoxidase activity) which converts hydroperoxides to epoxy-alcohols and ketones (70) (Figure 1B). eLOX3 has restricted dioxygenase activity (38), and its hydroperoxide isomerase activity is considered its primary catalytic reaction. Also, mammalian 5-LOXs and human 15-LOX-1 (ALOX15) possess leukotriene A₄ synthase activity which produces epoxides from hydroperoxides (71–74). The mechanism involves the homolytic cleavage of a hydroperoxide into an alkoxyl radical and hydrogen atom removal (via PCET) from a cis-allylic methane generating an alkyl radical. The resulting biradical is stabilized by epoxide formation (Figure 1C).

LOXs are inactive in their basal form with Fe(II) and require activation via oxidation into Fe(III) (Figure 1D). LOX activation is facilitated by hydroperoxides such as their dioxygenase reaction products. Although the proposed LOX catalytic cycle regenerates the ferric iron for another round of catalysis, small amounts of radical intermediates can escape the active site resulting in an incomplete catalytic cycle and requiring repeated activation of the enzyme (formation of Fe(III) by hydroperoxide) for sustained catalysis (69, 75, 76).

Some LOXs exhibit suicide inactivation, a property in which the reaction product rapidly inactivates the enzyme. Human 5-LOX is irreversibly inactivated by both of its products 5-HpETE and leukotriene A₄ (77). Similarly, rabbit reticulocyte 15-LOX (human 15-LOX-1 ortholog) is inactivated by its product 15-HpETE, and the mechanism is suggested to be through formation of reactive intermediates that covalently bind the enzyme (78). The dioxygenase reaction and the other two activities (lipohydroperoxidase and leukotriene synthase) have been proposed to inactivate LOXs through different mechanisms, but the mechanistic details remain unclear (78).

**LOXs Act on a Broad Range of Substrates**

LOX isoforms have different substrate preferences. Substrates of mammalian 5-LOXs include AA, its hydroperoxide product 5S-HpETE, as well as epoxy-alcohols derived from EPA and DHA (71, 79). The former two are important in the biosynthesis of leukotrienes, while the latter two are proposed to be precursors of E- and D-series resolvins, respectively (75, 80). 15-LOXs (ALOX15 and ALOX15B) accept AA, EPA, DHA, linoleic acid (LA), and γ-linolenic acid (GLA) as substrates. The preference of human 15-LOX orthologs is: DHA > EPA > AA > GLA > LA (18). One key difference is that 15-LOX-1 (ALOX15) possesses dual positional specificity for some of its substrates (e.g., 12 and 15-lipoxygenase activities for AA), whereas 15-LOX-2 (ALOX15B) exhibits singular specificity (15-lipoxygenase activity) (55). The hydroperoxide isomerase and epoxidase activities of 15-LOX-1 (ALOX15) are proposed to function in the synthesis of eoxins, E-series resolvins, and protectin from their respective precursors. Additionally, human 15-LOX-1 oxygenates PUFA-containing fatty amides and 2-arachidonoyl-glycerol ester (81, 82). Finally, mammalian 15-LOXs can catalyze the oxygenation of PUFA in lysophospholipids (lysoPL), PLs, CEs, and lipoproteins (83–88).

PUFA substrates of platelet 12S-LOX (ALOX12) include AA, EPA, DHA, and dihomo-γ-linolenic acid (DGLA) (18, 89). While no single study has compared all substrates at the same time, one determined the order of preference for the first three substrates to be: DHA > EPA > AA (18). Another found comparable kinetic parameters for EPA, AA, and DGLA as substrates (89). Both observed a singular positional specificity for 12S-LOX. LA, GLA, and α-linolenic acid (ALA) were all found to be poor substrates for 12S-LOX (18, 89, 90). Furthermore, human 12S-LOX possesses lipoxin synthase activity, which converts leukotriene A₄ into lipoxins A and B (91). The enzymatic activities of 12S-LOX are also proposed to function in the biosynthesis of hepxilins and maresins (92, 93). Recently, 12S-LOX was shown to oxygenate 2-AA-lysoPL, proposing alternate pathways for oxylipin and oxPL biosynthesis (94).

Mammalian 12R-LOX (ALOX12B) and eLOX3 (ALOX3) are co-expressed in skin and their functions are related. 12R-LOX efficiently catalyzes the peroxidation of AA, DGLA and GLA, and less efficiently LA, EPA and DHA (23, 24). Later, 12R-LOX was shown to oxygenate LA esterified to ω-hydroxyacyl-sphingosine more efficiently than free LA (25). The hydroperoxide product of this reaction is further converted into an epoxy-alcohol by the isomerase activity of eLOX3. These two reactions are essential for the proper formation of the water-impermeable barrier in corneocytes (25). Human eLOX3 isomerase activity has also been observed on the 12R- and 12S-hydroperoxides of AA, with the reaction occurring 2-3 times faster for the R-stereoisomer (95). These reactions produce hepxilins, which play a role in skin inflammation. Curiously, mouse 12R-LOX and eLOX3 metabolize the methyl esters of AA and LA more efficiently than the unmodified FAs (58). However, human and mouse orthologs are known to exhibit differences in substrate preference and regio-specificity (95). Thus, further work is needed to assess the ability of human 12R-LOX to metabolize fatty methyl esters and whether that reaction is biologically relevant.

Several aspects of LOX enzymology remain unresolved. First, the functional implications of suicide inactivation are unknown, that is, the reason why some LOXs have not evolved to resist suicide inactivation. This suggests a biological function for this property, perhaps in regulation. Additionally, the mechanistic details of suicide inactivation are not fully understood. Second, due to the ever-increasing list of LOX substrates, it has been difficult to pinpoint biologically relevant substrates and assign...
clear functions to all LOX isoforms. For example, the function of 15-LOX-2 (ALOX15B) in macrophages remains unclear, although it has been recently shown to regulate cholesterol levels (96). Unique substrates of each isoform (e.g., CEAs for 15-LOXs, lysoPLs for 12S-LOX) might be worth investigating.

**Cyclooxygenase (COX)**

**Human COX: Isoforms and Tissue Distribution**

Cyclooxygenases (COXs), also called prostaglandin-endoperoxide synthases and prostaglandin G/H synthases, are heme-containing enzymes that possess both oxygenase and peroxidase activities. There are two COX genes in humans: PTGS1 and PTGS2, which encode for COX-1 and COX-2, respectively. Traditionally, it was thought that COX-1 is constitutively expressed, whereas COX-2 is inducible in response to inflammatory signals. However, several studies suggest constitutive COX-2 expression in the brain, lungs, gut, thymus, kidneys, and blood vessels (97–99). In the vasculature, COX-2 has been demonstrated to be a key source of vascular prostacyclin (100, 101). COX-1 is ubiquitously expressed in the body, and its expression sites include blood vessels, prostate, immune cells (monocytes, T-cells), platelets, stomach, resident inflammatory cells, smooth muscles, and mesothelium of many organs (102–105). On the other hand, COX-2 is inducible in many tissues including prostate, immune cells (T-cells, B-cells, monocytes), and stomach (102–104, 106), but also constitutively expressed in some tissues as previously mentioned.

**Structure of COX**

The role of COXs as mediators of inflammation and their potential as drug targets were drivers for the elucidation of their structures. The crystal structure of sheep COX-1 has been solved in the presence and absence of various synthetic ligands (107–109). Similarly, there are available structures for mouse COX-2 in the presence and absence of natural and synthetic ligands (13, 110–113), as well as human COX-2 with several inhibitors (114, 115).

Both COX isoforms are homodimers, and this quaternary structure is necessary for enzymatic activity (116). Each monomer consists of three domains: An N-terminal epidermal growth factor (EGF)-like domain, a membrane binding domain, and a large C-terminal catalytic domain. The EGF-like domain is located at the dimer interface and potentially facilitates dimerization. It is also thought to facilitate membrane binding (117). The membrane binding domain consists of four amphipathic α-helices that insert into one face of a membrane bilayer. Both COXs are found on the luminal face of the endoplasmic reticulum (ER) and the inner and outer nuclear membranes (118). However, COX-2 is also found in the Golgi apparatus (119). The catalytic domain (in both isoforms) contains separate oxygenase and peroxidase active sites on opposite sides of the heme cofactor. The oxygenase active site is located towards the membrane binding face at the end of a hydrophobic tunnel that allows substrate entry, whereas the peroxidase active site is in a groove on the opposite face of the enzyme (120).

COXs undergo N-glycosylation at multiple asparagine residues. This facilitates their proper folding, and regulates the turnover of COX-2 by controlling its trafficking between the ER and the Golgi apparatus (119, 121, 122). COX-2 can also be S-nitrosylated by inducible nitric oxide synthase, which has been proposed to enhance its activity (123). *In vitro* experiments on recombinant human COX-1 and COX-2 demonstrated that both isoforms can be S-nitrosylated by a nitric oxide donor, but only COX-2 showed increased cyclooxygenase activity (124). Circular dichroism data suggest an altered, less dynamic conformation for both isoforms after S-nitrosylation with less α-helices, turns, and random coils, but more β-sheets. The structural change was more pronounced in COX-2 compared to COX-1. These findings provide new insight into the structural dynamics of COXs. The occurrence and biological relevance of this altered COX conformation is unexplored *in vivo* and would benefit from further investigation.

Although COXs are sequence homodimers, they are considered conformational heterodimers because one monomer functions as the catalytic subunit (E_{cat}) and the other as an allosteric regulator (E_{allo}) (125–127). For both COX isoforms, the binding of one heme molecule to E_{cat} is required for full activity. Several substrate and non-substrate FAs can bind E_{allo} to regulate the activity of E_{cat}, and the two COX isoforms exhibit differences in this regard. COX-1 is inhibited by palmitic acid, stearic acid, margaric acid and oleic acid (127), none of which are COX substrates. On the other hand, COX-2 is stimulated by palmitic acid and stearic acid (126). Substrate FAs (like AA and EPA) also bind to E_{allo} to regulate COX activity, with notable differences in the responses of the two isoforms (reviewed in (128)).

**Catalytic Mechanism of COX**

COXs possess two enzymatic activities: a dioxygenase activity and a peroxidase activity. The dioxygenase activity is a controlled peroxidation process (129), and the role of the enzyme is to direct hydrogen abstraction and the stereochemistry of formation of intermediates (120). Unlike LOXs where hydrogen abstraction is carried out by a non-heme associated Fe(III), hydrogen abstraction in COX is carried out by a catalytic tyrosyl radical (Figure 2A). The heme group oxidizes a tyrosine residue in the active site into a radical, which then abstracts a hydrogen (stereo- and regio-specifically) from the (1Z,4Z)-pentadiene group of the lipid. Using AA as an example substrate, the 13-pro-S hydrogen is abstracted. The resulting alkyl radical rearranges into a conjugated diene before the addition of dioxygen at C11, generating a peroxyl radical (11R-stereochemistry). Rotation of the peroxyl radical positions the outer oxygen atom in the correct orientation to attack the C9 carbon resulting in an endoperoxide (130). A second cyclization involving C8 and C12 generates a bicyclic ring and a radical at C15. Note that the cyclopentane ring is formed in the trans configuration (131). This differs from the non-enzymatically generated isoprostanes which occur predominantly in the cis configuration (132). Following the second cyclization, dioxygen is added onto the si face of the C15, forming a peroxyl radical (15S-stereochemistry). Hydrogen atom transfer from the active
site tyrosine residue forms prostaglandin G₂ (PGG₂) and regenerates the tyrosyl radical for another round of catalysis. The peroxidase activity of COX reduces PGG₂ into PGH₂ (Figure 2A). The mechanism involves a two-electron reduction of the hydroperoxide into an alcohol, with a corresponding oxidation of the heme group into the oxoferryl form (133) (Figure 2B). Regeneration of the heme group can be achieved by two sequential one-electron reductions. The peroxidase activity is required for the dioxygenase activity as the oxidation of the tyrosine into a radical is done by the oxoferryl-porphyrin cation radical generated during the peroxidase reaction cycle (133) (Figure 2B). Suicide inactivation has been described for both the dioxygenase and peroxidase activities of COX (133, 134).

The dioxygenase activity of COX can also result in a lipoxygenase-type reaction, in which one dioxygen molecule is introduced and no endoperoxide formation occurs (135, 136) (Figure 2A). In this case, the peroxyl radical formed after the addition of the oxygen is reduced into a hydroperoxide instead of participating in the cyclization reaction. This reaction represents an incomplete catalytic cycle and occurs as a side product. Using AA as a substrate, this lipoxygenase-type reaction (after

**FIGURE 2** | Reaction mechanism of cyclooxygenases (COXs). (A) Production of eicosanoids from arachidonic acid through the dioxygenase and peroxidase activities of COX. The cyclooxygenase reaction is colored black. Peroxidase reactions are coloured blue. Reactions that produce HpETEs are colored red. Side reactions that produce 15-HETEs are depicted by dashed arrows. (B) The peroxidase cycle generates the Tyr radical required for hydrogen abstraction (porphyrin ring of heme not shown).
reduction by peroxidase) leads to the formation of 11R-HETE (HETE: hydroxy-eicosatetraenoic acid), 15R-HETE and 15S-HETE (minor product compared to 15R-HETE in both isoforms) (137). C11 and C15 are the same oxygen insertion sites in the dioxygenase (cyclooxygenase reaction), and these by-products are thought to arise from alternate conformations of substrate in the active site (138).

Aspirin (acetylsalicylic acid) is an inhibitor of COXs, and its mechanism of action involves the acetylation of a serine residue (Ser530 in COX-2) in the active site. Acetylation of COX-1 leads to complete inhibition (139), whereas the acetylation of COX-2 promotes the lipoxygenase-type reaction and the formation of 15R-HETE (140). It was previously thought that acetylation completely inhibits PG production by COX-2 (cyclooxygenase reaction). However, recent evidence shows that the acetylated enzyme retains that activity (155-PG formation) but also more favorably forms 15R-PGs (141), although PGs are still minor products compared to 15R-HETE for acetylated-COX-2. These findings are consistent with an earlier study that reported the formation of 15R-PGE₂ in COX-2 Ser530 mutants (137). Thus, both acetylation and mutagenesis of Ser530 in COX-2 promote 15R-PG formation.

**COX Isoforms Differ in Their Substrate Specificity**

COXs catalyze the transformation of AA into PGH₂, which is a precursor of other PGs (PGD₂, PGE₂, PGF₃₀, PG₁₂) and thromboxane. These oxygenated AA derivatives are generated through the action of tissue-specific enzymes downstream of COX (discussed in section 3.1) and play roles in inflammation, blood flow regulation and blood clotting through interactions with specific GPCRs (142).

COXs also accept other PUFAs as substrates including DGLA, LA, ALA, EPA, and GLA (143), at least in vitro. An early study determined the efficiency of substrate utilization for human COXs (Kₐp/Kₘ) to be AA > DGLA > LA > ALA, with ALA being a poor substrate for COX-1. EPA and GLA are poor substrates for both isoforms but they are better substrates for COX-2 than for COX-1 (143). Later studies have tested other PUFAs like eicosadienoic acid, adrenic acid, docosapentaenoic acid and DHA as COX substrates (127, 144). In general, COX-2 was found to be more efficient than COX-1 for a broader range of PUFAs. That said, AA is the preferred substrate for both isoforms, but COX-2 can oxygenate it at lower concentrations compared to COX-1 due to differences in their allosteric regulation by FAs (145).

COX-2 can also catalyze the 11R-, 15R-, 15S-dioxygenation and bis-oxygenation of 5S-HETE, forming diHETEs in the former three reactions and a di-endoperoxide product in the later reaction. However, acetylation of COX-2 shifts the specificity into favoring 15R-dioxygenation producing 5S,15R-diHETE (146). Additionally, COX-2 can oxygenate AA in complex lipids for example; arachidonylethanolamide, 2-arachidonoylglycerol (2-AG), and N-arachidonoylglycine (147–149). Recently, 2-AA-lysoPL, and ethanolamide derivatives of EPA and DHA were also shown to be COX-2 substrates (88, 150). Oxygenation of AA-lysoPL by COX-2 generates eicosanoid-lysoPL, which can be hydrolyzed to release eicosanoids through intracellular lipases (88). The ability of COX-2 to bind and oxygenate a broader range of substrates compared to COX-1 has been attributed to a larger active site, the orientation of an Arg residue in the substrate binding pocket and amino acid residues lining the tunnel leading to the cyclooxygenase active site (13).

COX isoforms exhibit differences in expression, tissue distribution, allosteric regulation, and substrate specificity. However, some aspects of COX biochemistry are unclear. For example, the physiological functions of COX-2-derived oxygenated endocannabinoids are unclear. Additionally, COX-2 oxygenates AA-lysoPLs into eicosanoid-lysoPLs, which are proposed to function in signaling and as precursors to other mediators (88). However, the metabolism of eicosanoid-lysoPLs requires further investigation.

**Cytochrome P450 (CYP)**

**Cytochrome P450s (CYP) are a superfamily of heme-containing monoxygenases that are ubiquitous across all domains of life.** There are 57 functional CYP genes in humans, and their products are further divided into 18 families and 41 sub-families based on amino acid sequence (151, 152). A robust, unified nomenclature system has been devised for CYPs, encompassing all known CYPs across living organisms (153, 154). The name includes the root “CYP,” followed by a number for family, a letter for subfamily, and a gene-identifying number for isoforms. Additionally, an asterisk and a number are added at the end to denote alleles (155). Families and subfamilies are based on 40% and 55% amino acid sequence identity, respectively.

CYPs are widely distributed in mammalian tissues (156–158), with a particularly high expression in the liver, brain, kidney and lung. Intracellularly, mammalian CYPs are generally bound to mitochondrial membranes and the endoplasmic reticulum (ER); microsomes when in vitro (159, 160). There is also evidence of mammalian CYPs in other compartments including the plasma membrane and the nucleus, based on in vitro studies on cultured cells (161–164). Some microsomal CYPs are also targeted into the mitochondria (159). In the human genome, 50 out of the 57 functional CYP genes code for microsomal CYPs, and the remaining seven for mitochondrial isoforms. Some CYPs are inducible by environmental stimuli, whereas others are constitutively expressed (152). Induction of CYP expression by environmental compounds can be through interactions with nuclear receptors, transcriptional regulatory elements, or non-coding RNAs (165).

Two major functions of CYPs are in drug metabolism and lipid metabolism. Here, we focus on lipid metabolism which involves members of most human CYP family. For an extensive review, the reader is referred to Nelson and Nebert (166).

**Structure of Mammalian CYPs**

Structural characterization was first carried out on bacterial CYPs, which are typically water soluble. On the other hand, mammalian CYPs are membrane-bound, and initial attempts to crystallize them were unsuccessful until a small N-terminal hydrophobic helical segment was replaced with a hydrophilic sequence from a related protein. The first structure to be
CYPs consist of two domains: a β-sheet-rich N-terminal domain and a larger helix-rich C-terminal catalytic domain. The N-terminal domain in microsomal CYPs contains a transmembrane helix that plays a role in membrane anchoring, but that role is not exclusive as CYPs contain other regions (in the catalytic domain) that bind the membrane. This transmembrane helix is not present in mitochondrial CYPs, and their membrane binding is facilitated by hydrophobic and amphipathic regions on the surface (160, 168). The N-terminus also contains a signal peptide sequence for trafficking into the appropriate compartment, that in the case of mitochondrial CYPs, is cleaved during transport. The catalytic domain contains a deep cavity that houses the heme prosthetic group. A thiolate ion in a conserved cysteine residue occupies the fifth coordination position of heme, and a water molecule occupies the sixth position in the resting state. There is variable flexibility in the active site among CYPs, and a high degree of flexibility has been correlated to substrate promiscuity (169, 170). Residues in helices surrounding the active site heme position the substrate for catalysis. Additionally, in the CYP4 family, a covalent linkage has been identified between the heme group and a conserved glutamic acid residue (171), and this interaction plays a role in substrate positioning for ω-hydroxylation (hydroxylation at the methyl end of FAs) (172).

Other structural features of CYPs include access channels that allow entry of substrates from both the aqueous and membrane compartments and an exit channel for the product (160). Furthermore, oligomerization is well-documented in both microsomal and mitochondrial CYPs, which can be between subunits of the same CYP (homomeric; e.g., CYP2C2) or different CYPs (heteromeric; e.g., CYP2E1/CYP3A4 and CYP1A2/CYP2B4) (173–180). These interactions provide an additional layer of regulation and play a role in substrate specificity.

Enzymology of Mammalian CYPs

CYPs catalyze a wide range of reactions (181, 182), but the most common include C-hydroxylation, heteroatom oxidation, heteroatom dealkylation, epoxidation, and group migration (182). Many reactions of CYPs are dependent on their ability (owing to the thiolate-heme group) to catalyze the scission of dioxygen and incorporate one of the oxygen atoms into the substrate, with the other being reduced to water. These reactions require electron transfer from a donor, NADPH, to the heme iron. However, transfer of electrons from NADPH to CYPs requires protein partners: NADPH cytochrome P450 reductase in the case of microsomal CYPs, and the combined functions of adrenodoxin reductase and adrenodoxin in mitochondrial CYPs. Thus, CYPs form complexes with their redox partners, at least during catalysis. That said, not all CYP reactions require external oxygen or electron donors. Examples are isomerization reactions catalyzed by CYP5A1 (thromboxane synthase) and CYP8A1 (prostacyclin synthase) (183), two enzymes involved in PGH2 metabolism.

A generalized reaction mechanism for CYPs (Figure 3A) contains the following steps: starting with the resting state, substrate recruitment displaces H2O from the 6th (axial) position of the heme Fe(III). This is followed by a 1-electron reduction from a donor forming Fe(II), O2 binding, and another 1-electron reduction resulting in a negatively charged peroxo group. Protonation of this complex twice by nearby H2O or amino acid residues results in the scission of the dioxygen (O-O bond) into an oxoferryl intermediate (compound I) and a water molecule (184). Compound I is thought to be the direct oxidant in many CYP oxidation reactions (185). In hydroxylation reactions, compound I abstracts a hydrogen from an alkyl group in the substrate generating a carbon radical and an iron oxygen complex, which rapidly react together forming a hydroxyl group on the substrate and regenerating the heme iron into the Fe(III) state (Figure 3B). Although this is a generalized reaction scheme for CYPs, the intermediates following O2 binding until compound I have been difficult to characterize due to their instability and the exact electronic structures are not fully assigned (185).

Mammalian CYPs Play Crucial Roles in Oxidative Lipid Metabolism

CYPs are involved in the metabolism of a wide range of lipids including PUFAs and sterols (Table 2). Hydroxylation and epoxidation are two common CYP-mediated reactions for PUFA substrates. CYPs can hydroxylate FAs terminally (ω-hydroxylation) or midchain. Similarly, CYP-mediated epoxidation can occur on various double bonds in PUFA. CYPs exhibit variable preference with respect to the reaction type and positional specificity. CYP1-3 families catalyze epoxidation and hydroxylation reactions for FAs, whereas the CYP4 family favors hydroxylation over epoxidation, specifically ω-hydroxylation (204).

Terminal hydroxylation of AA by CYPs produces 20-hydroxyeicosatetraenoic acid (20-HETE), which functions in blood pressure regulation and water balance (205). Additionally, terminal hydroxylation functions in ω-oxidation (a catabolic pathway for FAs), the degradation of some eicosanoids (206, 207), and the proper formation of the skin permeability barrier (208). Midchain hydroxylation of PUFAs produces mono-hydroxylated derivatives (HETEs in the case of AA) with various bioactivities (reviewed in (152)). Unlike LOXs and COXs which oxygenate carbons two bonds away from bis-allylic methylene carbons, CYPs can also oxygenate bis-allylic carbons (producing 7-, 10- and 13-HETE from AA), and various other positions (209–211). However, bis-allylic hydroxylation products are unstable in mildly acidic conditions and rearrange into conjugated dienes (211).

Epoxidation of AA by CYPs produce epoxy-eicosatetraenoic acids (EET). However, other PUFA like LA, EPA and DHA also undergo CYP-mediated epoxidation. Epoxy derivatives of PUFAs are implicated in blood pressure regulation and inflammation (15). Their metabolism is undertaken by several epoxide hydrolases including soluble epoxide hydrolase (sEH).
FIGURE 3 | Reaction mechanism of cytochrome P450s (CYPs). (A) Generalized catalytic cycle of CYPs. (B) Hydroxylation of a generic substrate (R–H) by compound I via an oxygen rebound mechanism.
and microsomal epoxide hydrolase (mEH) (212). The action of epoxide hydrolases produces dihydroxy derivatives which possess different bioactivities from their epoxide precursors (15).

Arachidonoylthanolamide also undergoes CYP hydroxylation and epoxidation (213, 214). Similarly, CYPs catalyze epoxidation of EPA and DHA ethanolamides, producing compounds with anti-inflammatory and anti-angiogenic effects (215), suggesting a link between the CYP epoxygenase and endocannabinoid pathways. The metabolism and biological roles of these mediators is an active area of research (216).

CYPs catalyze several types of reactions in the metabolism of sterols, some of which involve multiple oxygenation/hydroxylation steps. Demethylation of lanosterol by CYP51A1 is a key reaction in cholesterol biosynthesis and involves three successive oxidations of a methyl group, resulting in its release as formic acid and the introduction of a double bond at the A ring (217). Similarly, the formation of estradiol from testosterone via the action of CYP19A1 (P450arom) involves the elimination of a methyl group by three successive oxidation steps and the introduction of a double bond at the A ring. Additionally, cholesterol side-chain cleavage by CYP11A1 (P450scc) involves two hydroxylation steps on different carbons followed by a C-C bond cleavage (218). This reaction produces pregnenolone which is a key intermediate in the formation of androgens, estrogens, glucocorticoids and mineralocorticoids.

CYP-mediated hydroxylation reactions are ubiquitous in cholesterol metabolism, leading to the formation of oxysterols, steroid hormones and bile acids. Key enzymes in the bile acid biosynthesis pathways are CYP7A1 (cholesterol 7α-hydroxylase), CYP8B1 (sterol 12α-hydroxylase), CYP27A1 (commonly named sterol 27-hydroxylase, but more correctly sterol 25R-26-hydroxylase) and CYP7B1 (oxysterol 7α-hydroxylase) (219, 220). Of these enzymes, CYP27A1 can both hydroxylate and carboxylate the terminal carbon of the sterol side-chain (221). Other enzymes involved in quantitatively minor bile acid biosynthesis pathways are CYP46A1 (cholesterol 24S-hydroxylase) which 24S-hydroxylates cholesterol (222, 223) and CYP3A4 which has 4α- and 25-hydroxylase activity (189, 224). CYP enzymes involved in steroid hormone biosynthesis include CYP11A1 (P450scc) (225), CYP17A1 (steroid 17α-hydroxylase) (226), CYP21A2 (steroid 21-hydroxylase), CYP11B1 (steroid 11β-hydroxylase), and 11B2 (aldosterone synthase) and CYP19A1 (aromatase) (198).

Thus, CYPs play indispensable roles in the metabolism of both PUFA and cholesterol. However, some human CYPs like CYP2A7 and CYP20A1 have no assigned functions and remain orphan enzymes.

### Human Aldo-Keto Reductases (AKRs) and Hydroxysteroid Dehydrogenases (HSDs)

#### AKRs: Nomenclature, Genes, and Tissue Distribution

Aldo-keto reductases (AKRs) are a superfamily of NADPH-dependent oxidoreductases. They catalyze the reduction of carbonyl groups to alcohols. A nomenclature system has been proposed for AKRs (227). Like CYPs, AKRs are grouped into families and subfamilies based on amino acid sequence. Families have 40% sequence identity, whereas subfamilies are defined by 60% sequence similarity. The nomenclature consists of the root structure followed by the family number.
“AKR” followed by a number for family, a letter for subfamily and finally a number as a unique gene identifier. The nomenclature has also been expanded to accommodate multimers (228). The older (trivial) names of AKRs are still heavily in use, which could lead to confusion. Thus, it is advised to follow the nomenclature system proposed by Jez et al. (227).

There are 15 AKRs in the human genome spanning three families and seven subfamilies. Human AKRs have variable expression and accept a wide range of substrates (Table 3). They are involved in the metabolism of sugars, prostaglandins and sterols, as well as the detoxification of carbonyl compounds like lipid peroxidation products. Additionally, members of family 6 (AKR6A3, AKR6A5, and AKR6A9) are constituents of voltage-gated potassium channels (250). All human AKRs have either established or proposed roles in lipid metabolism except for AKR1E2.

Human AKRs are generally cytosolic with some exceptions. AKR1B15 is found in mitochondrion (236). Members of the AKR1C subfamily in the lung (1C1, 1C2 and 1C3) are also secreted in pulmonary surfactant (256). AKR1B10 is present in lysosomes and is secreted into the intestinal lumen by epithelial cells (257). AKR6 members form a complex with a plasma membrane voltage channel on the cytosolic side. Finally, rat AKR7A2 associates with the Golgi apparatus (258). Human AKR7A2 contains a similar N-terminal amphipathic sequence and likely associates with the Golgi apparatus.

**Mammalian AKRs: Structure and Enzymology**

Crystal structures have been solved for many mammalian AKRs. They comprise of a triosephosphate isomerase barrel motif (α/β)8 which has alternating α-helices and β-strands repeating eight times. The α-helices surround an internal β-barrel formed by the β-strands. The active site is located at the base of the barrel, in which the substrate and the nicotinamide head group of NADPH (cofactor) are proximally positioned for the reaction, while three flexible loops form the back of the barrel and control substrate specificity (259, 260). The structure also contains two additional helices that are not part of the barrel motif. Family 1 AKRs are monomeric, whereas families 6 and 7 form tetramers and dimers, respectively (258, 261).

AKRs catalyze the stereospecific reduction of carbonyls into alcohols. They can also catalyze the reverse oxidation reaction. However, the reducing direction is generally favored due to the abundance of reduced cofactor in the cellular environment. AKRs can use both NADPH and NADH, but NADPH is the preferred cofactor for most known AKRs as they interact with the phosphoryl group present in NADPH but not NADH (262, 263). The stereospecific nature of the reaction is due to the orientation of the NADPH and the substrate in the active site. The NADPH is bound in the anti-conformation (with respect to the ribose ring) which promotes the transfer of the 4-pro-R hydride (264), and the substrate is positioned perpendicular to the cofactor.

The reaction of AKRs follows an ordered bi-bi mechanism in which the NADPH cofactor binds first and leaves last. The active site of AKRs contains a highly conserved catalytic tetrad of Tyr, Lys, Asp and His. The hydride transfer is facilitated by acid-base catalysis involving the protonation state of Tyr and the other catalytic residues. In the reduction direction, the protonated form of Tyr acts as an acid by participating in proton relay.

---

**Table 3** | Human AKRs: Genes, expression sites, and example substrates.

| Gene       | Alternative protein name             | Expression sites       | Example substrates                                                                 | Refs.          |
|------------|--------------------------------------|------------------------|------------------------------------------------------------------------------------|----------------|
| AKR1A1     | Aldehyde reductase                    | Brain, kidney, liver, small intestine | 4-HNE, acrolein, succinic semi-aldehyde, D-glucuronic acid, phospholipid aldehydes | (229, 230),   |
| AKR1B1     | Aldose reductase/Prostaglandin F synthase | Ubiquitous             | Glucose, 4-HNE & its glutathione conjugate, acrolein, PGH2, phospholipid aldehydes | (229, 230),   |
| AKR1B10    | Small intestine aldose reductase      | Small intestine, colon, liver, cornea | Farnesal, retinoids, acrolein, phospholipid aldehydes | (229, 231–235), |
| AKR1B15    | Aldehyde-keto reductase/3-Keto-acyl CoA reductase | Placenta, testis, adipose tissue | Androgens, estrogens, 3-keto-acyl CoA conjugates | (236)          |
| AKR1C1     | 20α-HSD                              | Kidney, lung, liver, testis, brain | Progesterone, estrone, 5α-dihydrotestosterone, 4-HNE                                 | (230, 237–239),|
| AKR1C2     | Type 3 3α-HSD                        | Liver, brain, lung, prostate | Progesterone, estrone, 5α-dihydrotestosterone                                         | (237, 238),   |
| AKR1C3     | Type 5 17β-HSD/Prostaglandin F synthase | Liver, lung, prostate, brain, breast, lymphocytes | Progesterone, estrone, 5α-dihydrotestosterone, PGH2, PGD2, 4-HNE                      | (238, 240–242),|
| AKR1C4     | Type 1 3α-HSD                        | Liver                   | 3-Keto-5β-sterols, 5α-dihydrotestosterone                                             | (230, 238),   |
| AKR1D1     | Steroid 5β-reductase                  | Liver, placenta, brain  | Δ4-Ketosteroids, particularly bile acid intermediates                                 | (237, 243–245),|
| AKR1E2     | 1,5-Anhydro-D-fructose reductase      | Liver, testis           | 1,5-Anhydro-D-fructose                                                               | (246, 247),   |
| KONB1      | Potassium voltage-gated channel β-subunit-1 (Kvβ1)/AKR6A3 | Brain, heart             | Methylglyoxal, acrolein, 4-ONE, oxPL, PGJ2*                                           | (248, 249),   |
| KONB2      | Potassium voltage-gated channel β-subunit-2 (Kvβ2)/AKR6A5 | Brain, spinal cord       |                                                    |                |
| KONB3      | Potassium voltage-gated channel β-subunit-3 (Kvβ3)/AKR6A9 | Brain                   | No data.                                                                            | (253)          |
| AKR7A2     | Aflatoxin aldehyde reductase (AFAR1) | Ubiquitous              | Aflatoxin B1, succinic semi-aldehyde, 4-HNE                                           | (230, 254),   |
| AKR7A3     | Aflatoxin aldehyde reductase (AFAR2) | Liver, stomach, pancreas, kidney |                                                    | (255),         |

*Evidence from work on the rat ortholog. 4-HNE, 4-hydroxy-2-nonenal; 4-ONE, 4-oxo-2-nonenal; HSD, hydroxysteroid dehydrogenase; oxPL, oxidized phospholipid; PG, prostaglandin (e.g., PGH2, PGD2, PGJ2).
with His (259) (Figure 4A). This polarizes the carbonyl group of the substrate, allowing it to accept a hydride ion from the cofactor. In the oxidation direction, the phenolate form of Tyr (generated through proton relay with Lys and Asp) acts as a base and abstracts a proton from the alcohol group of the substrate, facilitating hydride transfer to the cofactor (259) (Figure 4B).

AKR1D subfamily members catalyze the irreversible 5\(\beta\)-reduction of sterol double bonds into single bonds, instead of the reversible reduction of carbonyls typical of AKRs (Figure 4C). They possess an altered catalytic tetrad with Glu replacing His (265). This substitution allows the substrate to penetrate deeper into the active site pocket, positioning C5 close to the 4-pro-H of NADPH (259). The catalytic Glu residue is thought to act as a superacid, facilitating the enolization of the steroid double bond and allowing hydride transfer to C5 (259, 265).

Human AKR1B1 catalyzes the isomerization of PGH\(_2\) to PGD\(_2\) in the absence of cofactor, as well as the reduction of PGH\(_2\) to PGF\(_{2\alpha}\) in the presence of cofactor (266). Curiously, both of these reactions are reported to be facilitated by a catalytic triad of Lys, His and Asp, without the involvement of Tyr in catalysis, although Tyr is still required for the \(p\)-nitrobenzaldehyde reductase activity of the enzyme (266). Thus, both Tyr and His can participate in acid-base catalysis, at least in AKR1B1.

**Involvement of Human AKRs in Lipid Metabolism**

Human AKRs play roles in the detoxification of reactive carbonyls. Several AKRs metabolize lipid peroxidation-derived aldehydes like acrolein and 4-HNE (Table 3). Additionally, some AKRs (1A1, 1B1, 1B10, 6A5) can reduce oxidized phospholipids, particularly phospholipid aldehydes (229, 251). These activities mitigate the cytotoxicity of reactive carbonyls (240, 267–269), and in the case of family 6 AKRs are also thought to function in redox sensing (251).

Both AKR1B1 and AKR1C3 exhibit prostaglandin F synthase activity (270, 271). AKR1B1 catalyzes the reduction of PGH\(_2\) to PGF\(_{2\alpha}\). AKR1C3 catalyzes the same reaction as well as the
reversible reduction of PGD₂ to 9α,11β-PGF₂ (241). Furthermore, AKR1B1 catalyzes the isomerization of PGH₂ to PGD₂ exclusively in the absence of NADPH as noted previously. However, the biological relevance of this activity is not clear as this isomerization reaction is also catalyzed by two prostaglandin D synthases (272), and the cellular redox status favors the reduction reaction. Both PGF₃α and its isomer 9α,11β-PGF₂ promote uterine contractions during labor (237).

Six of the 15 human AKRs are involved in sterol/steroid metabolism: AKR1B15, the four members of the AKR1C subfamily (also grouped as hydroxysteroid dehydrogenases; HSDs), and AKR1D1. AKR1B15 catalyzes the 17β-reduction of androgens and estrogens (236). AKR1C1 (20α-HSD) catalyzes the 20α-reduction of progesterone inactivating it (273), whereas AKR1C2 (Type 3 3α-HSD) possesses a 3α-dehydrogenase activity and deactivates 5α-dihydrotestosterone (259). AKR1C3 (Type 5 17β-HSD) exhibits 17-ketoreductase activity and produces testosterone and estradiol from their respective precursors.

AKR1D1 and AKR1C4 (Type 1 3α-HSD) catalyze key steps in bile acid biosynthesis. AKR1D1 catalyzes irreversible 5β-reduction of a double bond in 3-ketosterols. This modification changes the geometry of the steroid nucleus from flat to twisted, with a bend in the A/B ring junction. Next, AKR1C4 catalyzes the 3α-reduction of the ketosteroid, resulting in a 3α,5β-configuration, a characteristic feature of bile acids.

Other HSDs Belong to the Short-Chain Dehydrogenase/Reductase (SDR) Family

Some HSDs belong to a different family of enzymes: the short-chain dehydrogenases/reductases (SDR). SDRs exhibit key differences from AKRs in structure, kinetics, catalytic mechanism, and reaction stereochemistry (reviewed in (274)). Of note, HSDs of the SDR family work as either ketosteroid reductase or hydroxysteroid oxidases, depending on their preference for the corresponding forms of NADP(H) or NAD (H). This contrasts with HSDs of the AKR1C family which operate in the reduction direction using (primarily) NADPH (274). Like CYPs and AKRs, a systematic nomenclature has been proposed for SDRs (275). However, the old names (especially for HSDs) remain heavily in use. HSDs of the SDR family have important functions in sterol/steroid metabolism (Table 4).

### BIOSYNTHETIC PATHWAYS OF OXIDIZED LIPIDS

#### Oxygenated PUFA and Oxidized Phospholipids

**Classification of Oxygenated PUFA as Eicosanoids and Docosanoids**

The term “oxylipin” refers to oxygenated PUFA derivatives. It encompasses a wide range of oxidized lipids like hydroxy-, epoxy-, o xo-FAs, and endoperoxides. Oxylipins can be classified according to their precursor into eicosanoids (C20) or docosanoids (C22), etc., and this system will be used from here on. Following the classification system of the LI DMAP consortium, eicosanoids include prostaglandins, leukotrienes, thromboxanes, lipoxins, heparins, E-resolvins, as well as hydroxy-, hydroperoxy-, epoxy-, and o xo-eicosanoids (286). Likewise, docosanoids include D-resolvins, protectins, maresins, hydroxy-, hydroperoxy-, epoxy-, and o xo-docosanoids. Structures of these lipids are available on the LI DMAP database (287).

Here, we focus on the biosynthesis of eicosanoids derived from AA and EPA, and docosanoids derived from DHA, as they are the most studied. Due to the broad substrate specificity of enzymes involved in lipid oxidation, PUFAs with shorter chains or different number of double bonds also undergo similar reactions. Similarly, oxygenation of endocannabinoids occurs on the PUFA moiety and follows the enzymatic mechanisms described here. Further aspects of oxygenated endocannabinoids are discussed in other reviews (216, 288).

#### Release of PUFA from Membranes for Oxylipin Biosynthesis

Intracellular concentration of free PUFA is tightly regulated through conjugation with coenzyme A (CoA) and subsequent esterification into lysoPL forming PL or shuttling into other pathways (like β-oxidation). PUFAs are abundant in membrane PLS, typically esterified at the sn-2 position. The classical pathway of oxylipin biosynthesis involves the release of PUFA from membrane PL via the action of lipases like phospholipase A₂ (PLA₂), phospholipase C and diacylglycerol lipase (289, 290). PLA₂ enzymes are classified into six types: secreted (sPLA₂), cytosolic (cPLA₂), calcium-independent (iPLA₂), platelet-activating factor...

### Table 4 | Human SDR-HSDs and their substrates/reactions.

| Gene | Alternative protein names | Substrates | Reaction | Refs. |
|------|--------------------------|------------|----------|-------|
| HS03B1 | Type 3 3β-HSD/Δ⁴⁺⁺ isomerase/SDR11E1 | 3β-Hydroxy-Δ⁴⁺⁺-sterols | Oxidation & isomerization | (276, 277) |
| HS03B2 | Type 2 3β-HSD/Δ⁴⁺⁺ isomerase/SDR11E2 | 3β-Hydroxy-Δ⁴⁺⁺-sterols | Oxidation & isomerization | (277, 278) |
| HS03B7 | Type 7 3β-HSD/SDR11E3 | 3β-Hydroxy-Δ⁴⁺⁺-sterols | Oxidation & isomerization | (279) |
| HSD11B1 | Type 1 11β-HSD/Corticosteroid 11β-dehydrogenase isozyme 1/SDR26C1 | 11β-Hydroxysterols (e.g. cortisol), | Oxidation | (280) |
| HSD11B2 | Type 2 11β-HSD/Corticosteroid 11β-dehydrogenase isozyme 2/SDR9C3 | 11β-Hydroxysterols (e.g. cortisol), | Oxidation | (280) |
| HSD17B1 | Type 1 17β-HSD/Estradiol 17β-dehydrogenase 1/SDR28C1 | Estrogens and androgens | Reduction | (281, 282) |
| HSD17B4 | Type 4 17β-HSD/Peroxisomal multifunctional enzyme type 2/SDR8C1 | (24R,25R)-3α,7α,12α,24-Tetrahydroxy-5β-cholostan-26-oyl-CoA | Reduction | (283) |
| HSD17B7 | Type 7 17β-HSD/3-Ketosteroid reductase/SDR37C1 | 3β-Hydroxysterols, 17β-estradiol | Reduction | (284, 285) |
acetylhydrolases (PAH-AH), lysosomal (LPLA2), and adipose (AdPLA), and these are further divided into groups and subgroups (291, 292). cPLA2α is localized in the cytosol but translocates to intracellular membranes upon calcium activation, and exhibits selectivity for phospholipids containing AA at the sn-2 position (293, 294). On the other hand, the release of DHA from the membrane can be facilitated by iPLA2β (295, 296). Last, sPLA2 enzymes are involved in the release of AA, EPA and DHA (297, 298). PLA2 enzymes are extensively reviewed by Murakami (299).

**Biosynthesis of Eicosanoids**

Arachidonic acid is a substrate of eicosanoids produced through the actions of COXs, LOXs, CYPs, and other downstream enzymes (Figure 5A). The most established of these are mono-oxygenation products of AA, DHA, and EPA and classic prostaglandins, leukotrienes, and thromboxane from COXs, LOXs, and CYPs. Most of these were described from the 1950s–90’s in seminal studies, with many conducted at the Karolinska Institute in Stockholm by Sune Bergstrom, Bengt Samuelsson and colleagues. Indeed, the Nobel Prize for Physiology and Medicine was awarded for discovery of prostaglandins and related biologically active substances in 1985 to Bergstrom, Samuelsson and John Vane. More recently, research has focused on characterization of multiply oxygenated PUFAs from AA, EPA, and DHA including several which are proposed to form from transcellular sequential oxygenation by

---

**FIGURE 5** Biosynthesis of eicosanoids derived from: (A) Arachidonic acid and (B) Eicosapentaenoic acid. HETE, hydroxy-eicosatetraenoic acid; Hp, hydroperoxy; Ep, epoxy; LTA4H, leukotriene A4 hydrolase; LTC4S, leukotriene C4 synthase; GGT, γ-glutamyl transpeptidase; DPEP2, dipeptidase 2; sEH, soluble epoxide hydrolase; 12-HEDH, 12-hydroxyeicosanoid dehydrogenase; PGES, prostaglandin E synthase (m: microsomal, c = cytosolic); PGDS (prostaglandin D synthase (L: lipocalin type, H: hematopoietic); 15-PGDH, 15-hydroxyprostaglandin dehydrogenase; PG-9KR, prostaglandin 9-ketoreductase; EET, epoxyeicosatetraenoic acid; DiHETrE, dihydroxy-eicosatrienoic acid; HEPE, hydroxy-eicosapentaenoic acid.
various enzymes. However, for many of these, their specific biosynthetic pathways, enantiomeric composition and biological actions in tissues are not well understood and the levels formed are extremely low in comparison to classic PGs and monohydroxy-oxylipins. Furthermore, their bioactions often require amounts of lipids that are considerably higher than levels detected in cell and tissue samples, and thus could be considered pharmacological.

COXs convert AA into PGG2 which is reduced into PGH2 (Figure 5A). From there, PGH2 functions as substrate for classic PGs and thromboxane, generated by tissue-specific enzymes. CYP5A1 (thromboxane synthase) is expressed in several cell types and tissues (platelets, macrophages, lung, kidney, liver) and catalyzes the isomerization of PGH2 into thromboxane A2, a potent vasoconstrictor and activator of platelet aggregation (300, 301). CYP5A1 also catalyzes the cleavage PGH2 into malondialdehyde and 12-hydroxyheptadecatrienoic acid. CYP8A1 (prostacyclin synthase) is widely expressed (abundant in ovary, heart, lung, skeletal muscle, and prostate) and catalyzes the isomerization of PGH2 into prostacyclin (PGI2), a vasodilator and inhibitor of platelet aggregation (302).

PGH2 can also be converted into PGD2 through the action of AKR1B1 or PGD synthases, of which there are two isoforms: lipocalin-type PGD synthase (in the central nervous system, male genitalia, heart, cerebrospinal fluid and plasma) and hematopoietic PGD synthase (in antigen-presenting cells, mast cells and megakaryocytes) (266, 303). PGD2 plays roles in the regulation of body temperature, sleep cycle, pain perception and the immune response (304). In the uterus, AKR1C3 catalyzes the reduction of PGD2 into 9α,11β-PGF2β, which promotes uterine contractions (237). Similarly, AKR1C3 and AKR1B1 catalyze the reduction of PGH2 into PGFαβ, which also promotes uterine contractions (305). Finally, PGH2 can be converted into PGE2 via the action of PGE synthases, of which there are three isoforms: an inducible microsomal isoform (mPGES-1), a constitutive microsomal isoform (mPGES-2) and a constitutive cytosolic isoform (cPGES) (306). PGE2 is abundant in the body and plays a complex role in immunity and inflammation (307). Additionally, PGE2 is reduced into PGF2α by prostaglandin 9-ketoreductase (PG-9KR) (308).

COXs also produce 11R-, 15R-, and 15S-HpETEs as side products, all three of which can be reduced into their corresponding alcohols by peroxidase activity, which are in turn reduced into oxo-ETEs by 15-hydroxyprostaglandin dehydrogenase (15-PGDH). Bioactivities of HETEs and oxo-ETEs are extensively reviewed by Powell and Rokach (309).

5-LOX converts AA into 5S-HpETE (Figure 5A), which is reduced into 5S-HETE through the action of a peroxidase (e.g., GPX) or converted into leukotriene A4 (LTA4) through the leukotriene synthase activity of 5-LOX. Various immune cells (neutrophils, monocytes, platelets) express 5-hydroxyeicosanoid dehydrogenase (5-HEDH) which converts 5S-HETE into 5-oxo-HETE, a potent chemoattractant for eosinophils (310). On the other hand, LTA4 serves as a precursor for LT peptide conjugates (LTC4, D4 and E4) and lipoxins (A and B). LTC4, D4, and E4 are synthesized from LTA4 through LTC4 synthase (a gluthathione-S-transferase), γ-glutamyl transpeptidase (GGT) and dipeptidase 2 (DPEP2). Leukotrienes exhibit pro-inflammatory properties and are implicated in asthma and allergic reactions (311). On the other hand, lipoxins are thought to be synthesized by 12S-LOX through a transcellular pathway which involves interactions between two cell types (312). Lipoxins exhibit anti-inflammatory properties and are proposed to play a role in wound healing and tissue homeostasis (313). Alternatively, LTA4 can be hydrolyzed by leukotriene A4 hydrolase (LTA4H) into LTB4, which attracts neutrophils (314).

15-LOXs convert AA into 15S-HpETE (Figure 5A), which can be reduced into 15S-HETE then oxidized into 15-oxo-ETE. 15S-HpETE and 15S-HETE are also substrates for 5-LOX, which produces a 5S,6S epoxy intermediate that can be hydrolyzed into lipoxins by unidentified hydroxylases. Additionally, 15S-HpETE is proposed to be a precursor for eoxin A4 (a 14,15 leukotriene), which is converted into peptide conjugates (eoxin C4, D4, and E4) similar to leukotrienes (315). Conversion of eoxin A4 into C4 is thought to involve LTC4S. Enzymes that catalyze the following two steps leading to eoxin D4 and E4 are unidentified, presumably a GGT isoform and DPEP2. Eoxins are produced in eosinophils, mast cells and airway epithelial cells, and have been shown to possess pro-inflammatory properties (316).

12S-HpETE and 12R-HpETE are produced by 12S-LOX and 12R-LOX, respectively (Figure 5A). These hydroperoxides can be reduced to their corresponding alcohols via a peroxidase, and both alcohols further oxidized into 12-oxo-ETE by 12-hydroxyeicosanoid dehydrogenase (12-HEDH) (309). Both hydroperoxides are also precursors for hepoxilins, which are epoxy-alcohols. eLOX3 in skin converts 12R-HpETE into either hepoxilin A3 or 12-oxo-ETE. On the other hand, 12S-HpETE can be converted into hepoxilin A3 or B3 by either 12S-LOX or eLOX3, but eLOX3 also generates 12-oxo-ETE (70, 317). Hepoxilins A3 and B3 are hydrolyzed by sEH into trioxilins A3 and B3, respectively (318). Hepoxilin A3 can also be conjugated with glutathione via LTC4S producing hepoxilin A3-C, which can be converted into a hepoxilin A3-D by GGT (319). The occurrence of hepoxilin A3-E (cysteinyl conjugate) has also been proposed but not confirmed. Hepoxilin A3 is proposed to regulate mucosal inflammation by recruiting neutrophils across the epithelial junction into the gut lumen (320).

CYPs generate various midchain R- and S-HETEs as well as 20-HETE through hydroxylation of AA (Figure 5A). Alternatively, epoxidecoatrienioic acids (EET) are produced from AA through epoxidation of its double bonds. Major mammalian CYP epoxigenases include CYP2C8, CYP2C9, and CYP2J2 (15). EETs are further metabolized by sEH (and potentially other epoxide hydrolases) into dihydroxyeicosatrienioic acids (DiHETE). Note that EPA and other PUFA are also targets of CYP-mediated reactions, which generate the corresponding hydroxy-, epoxy-, and dihydroxy- derivatives.

“E-resolvins”, another class of eicosanoids, are proposed to be generated from EPA (Figure 5B). COX-2 and CYPs have both been proposed to act on EPA to produce 18R-hydroxyeicosapentaenoic acid (18R-HEPE), which is in turn a proposed precursor for lipids

Frontiers in Endocrinology | www.frontiersin.org 16 November 2020 | Volume 11 | Article 591819
termed resolvins E1, E2 and E3 (E-resolvins). It is known that the acetylation of COX-2 shifts its activity into favoring the lipoxygenase-type reaction over the cyclooxygenase activity, and that acetylated COX-2 generates 18R-HEPE from EPA (321). However, acetylated COX-2 is not a physiologically relevant form, and 18R-HEPE could be potentially generated through other means. COX-2 is theoretically capable of generating 18R-HEPE from EPA in a lipoxygenase-type reaction followed by peroxidase activity. However, whether the generation of 18R-HEPE from EPA occurs in vivo and in sufficient amounts without COX-2 acetylation is unknown. Microbial CYPs have also been proposed as sources of 18R-HEPE during infection. E-resolvins are proposed to be produced through a transcellular mechanism involving microbial and mammalian cells (322). Alternatively, mammalian CYPs are also potential sources of 18R-HEPE, although the exact isoforms involved are unknown.

18R-HEPE can be metabolized by 5-LOX into a 5S-hydroperoxy intermediate and further into a 5S,6S-epoxy intermediate (323). The former is proposed to be converted into resolvin E2 by a peroxidase, whereas the latter is proposed to be hydrolyzed into resolvin E1 by LTA4H (324). 18S-analogues of resolvin E1 and E2 have also been described and are proposed to be generated from 18S-HEPE through a similar pathway (Figure 5B), although the enzymatic sources of 18S-HEPE (aside from acetylated COX-2) are also unknown. 18R-HEPE is also proposed to be a precursor to two stereoisomers collectively called resolvin E3 generated by 15-LOX-1 (325).

E-resolvins are proposed to exhibit anti-inflammatory effects and promote the resolution of inflammation (325, 326).

Both lipoxins and E-resolvins have been classified as specialized pro-resolving mediators (SPMs), a term which currently describes families of oxygenated PUFA metabolites with proposed roles in the resolution of inflammation and tissue regeneration generated at extremely low levels in biological samples.

**Biosynthesis of Docosanoids**

Oxygenation of DHA by LOXs and CYPs forms oxygenated docosanoids (hydroxy-, epoxy-, and dihydroxy derivatives). DHA is also the precursor to several classes of multiply oxygenated docosanoids, including additional SPMs which have been named maresins, D-resolvins, and protectins (Figure 6). Maresin biosynthesis has been proposed to start with action of 12S-LOX, generating 14S-hydroperoxy-DHA (14S-HpDoHE) then a 13S,14S-epoxy intermediate. Hydrolysis of this epoxy intermediate by sEH or an unidentified hydrolase is proposed to generate maresin 2 and maresin 1, respectively (93, 327). The biosynthesis of protectin and D-resolvins both begin with 15-LOX-1 which generates a 17S-hydroperoxide (17S-HpDoHE). Further conversion of this hydroperoxide into a 16S,17S-epoxy intermediate by 15-LOX-1 followed by hydrolysis (unidentified hydrolase) is proposed to generate protectin D1 (328). Alternatively, 17S-HpDoHE could be reduced into an alcohol by a peroxidase, which then serves as a precursor for D-resolvins. In this route, 5-LOX is proposed to generate two distinct products hydroperoxides (4S or 7S), which

---

**FIGURE 6** | Biosynthesis of specialized pro-resolving mediators (SPMs) derived from docosahexaenoic acid. HDoHE, hydroxy-docosahexaenoic acid; Hp, hydroperoxy; Ep, epoxy; CTR, conjugate in tissue regeneration (M: maresin, P: protectin, R: resolvin); sEH, soluble epoxide hydrolase; LTC4S, leukotriene C4 synthase; GGT, γ-glutamyl transpeptidase; DPEP2, dipeptidase 2.
undergo further transformations leading to several D-resolvins (Figure 6). Additionally, epoxide intermediates in the previously described pathways are proposed to undergo glutathione conjugation by LTC4S, generating peptide conjugates of maresin, protectin and D-resolin named MCTR1, PCTR1, and RCTR1, respectively (CTR = conjugate in tissue regeneration). These conjugates are proposed to be metabolized by GGT and DPEP2, similar to leukotrienes (329).

**Oxygenation of Esterified PUFA and Biosynthesis of Oxidized Phospholipids**

The classical pathway for the biosynthesis of oxidized phospholipids starts with the release of PUFA from membranes through the action of PLA2. PUFA are then oxygenated by the enzymes discussed earlier. This is followed by acylation of oxygenated PUFA with CoA and esterification into a lysoPL via the action of an sn-2 acyltransferase.

The generation of PL-esterified eicosanoids is well-documented in mammalian cells such as epithelial, endothelial and immune cells (330). HETE-PLs are acutely generated by activated neutrophils, platelets and monocytes (331–333). Similarly, PGD2 and PGE2 generated from COX-1-derived PGH2 in activated platelets are rapidly incorporated into PE-lysoPLs (334). Also, EET-PLs have been detected in rat liver (335). For most of these, the mechanism of formation requires endogenous generation of an oxylipin, which is then rapidly esterified into membrane PL pools (e.g., on a timescale of minutes) via Lands cycle enzymes (336).

15-LOXs also contribute to the formation of oxPL by two other pathways. The first involves direct oxygenation of membrane PLs (331, 337). In the second pathway, 15-LOXs oxygenate the PUFA moiety of CEs, then hydrolysis of oxygenated PUFA from CE liberates oxygenated PUFA which can be esterified to lysoPL (87).

Recent studies found that COX-2, 15-LOX-2, and platelet 12S-LOX can catalyze the oxygenation of 2-AA-lysoPL released by iPLA2 in response to calcium ionophore stimulation (88, 94). These reactions generate 2-eicosanoid-lysoPLs which are proposed to be a source of free eicosanoids as well as acting as signaling mediators themselves. 2-eicosanoid-lysoPLs can also be converted into oxPLs through the action of sn-1 acyltransferase (338). Cytochrome c has been recently been identified as a plasmalogenase, and is proposed to be a source of 2-eicosanoid-lysoPLs under conditions of oxidative stress (339). These findings describe novel pathways for the biosynthesis of oxPLs (Figure 7). Further research is required to assess the contribution of these pathways to the formation of oxPLs and other mediators in vivo.

**Biosynthesis of Oxysterols, Bile Acids, and Steroid Hormones**

**Oxysterols**

Oxysterols are formed in the first steps of cholesterol metabolism: they are oxidized forms of cholesterol and also of its precursors (340). 7α-Hydroxycholesterol (7α-HC) is formed from cholesterol by CYP7A1 and represents the first metabolite in the neutral pathway of bile acid biosynthesis (Figure 8) (219, 220). (25R)26-Hydroxycholesterol (26-HC), more commonly called 27-hydroxycholesterol, and 3β-hydroxycholest-5-en-(25R)26-oic acid (3β-HCA) are both formed from cholesterol by CYP27A1 and are the first members of the acidic or alternative pathway of bile acid biosynthesis (219–221). While CYP7A1 is an endoplasmic reticulum and liver specific protein, CYP27A1 is mitochondrial and expressed in many tissues. CYP46A1 is almost exclusively expressed in neurons, its function is to maintain cholesterol balance in the brain, converting cholesterol from a molecule unable to pass the blood brain barrier to 24S-hydroxycholesterol (24S-HC), a more polar molecule which can cross the barrier (222, 223, 341). CYP11A1, like CYP27A1, is a mitochondrial inner membrane protein. It is highly expressed in steroidogenic tissue and will oxidize cholesterol to pregnenolone in a three step process involving 22R-hydroxycholesterol (22R-HC) and 20β,22R-dihydroxycholesterol as intermediates (20R,22R-diHDC) (342, 343) (Figure 9). The pathways of bile acid biosynthesis are discussed in more detail below.

While most “primary” oxysterols are formed from cholesterol in CYP catalyzed reactions, cholesterol 25-hydroxylase (CH25H), the dominating enzyme that generates 25-hydroxycholesterol (25-HC) is an exception, in that is not a CYP, but a member of a family of enzymes that utilize di-iron cofactors to catalyze the hydroxylation (344). CH25H is expressed in activated immune cells and 25-HC has both antibacterial and anti-viral activities (345–348). 25-HC is metabolized by CYP7B1 to 7α,25-diHDC, a ligand to the GPCR Epstein Barr virus induced gene 2 (EBI2 or GPR183). 7α,25-dihydroxycholesterol (25-HC) acts as a chemoattractant to GPR183 expressing immune cells (349, 350). An alternative route to 7α,25-dihydroxycholesterol is through CYP3A4 oxidation of 7α-HC (190), while the same enzyme has also been reported to act as a second cholesterol 25-hydroxylase and also a 3β-hydroxylation of cholesterol (189, 351).

Oxysterols can also be formed from cholesterol precursors in reactions catalyzed by CYP enzymes (202, 352). These reactions may be important in patients suffering from inborn errors of cholesterol biosynthesis such as Smith-Lemli-Opitz syndrome (SLOS, 7-dehydrocholesterol reductase deficiency) and desmosterolosis (3β-hydroxysterol-Δ24-reductase deficiency) or where there is very high expression of sterol hydroxylases, e.g., CYP7A1 in cerebrotendinous xanthomatosis, where CYP27A1 is deficient.

**Bile Acid Biosynthesis**

There are two quantitatively major and at least five minor pathways of bile acid biosynthesis and all pathways involve multiple oxidation reactions (219, 220, 353–358). Besides CYP enzymes, key oxidation reactions are carried out by hydroxysteroid dehydrogenase (HSD) members of the short chain dehydrogenase/reductase (SDR) family and reductions by aldo-keto reductases (AKR) enzymes. One of the minor pathways that results in the formation of 3β,5α,6β-trihydroxycholan-24-oic acid involves of cholesterol-3β,5α,6β-triol which is likely formed via the cholesterol peroxidation product 5,6-epoxycholesterol (219, 354).
While the acidic pathway may be most important in infants (359), at later stages of life the neutral pathway is dominant. This is initiated by CYP7A1 oxidation of cholesterol to generate 7α-HC in the liver. Further oxidation may occur at C-12 by CYP8B1 to generate 7α,12α-dihydroxycholesterol (7α,12α-diHC), which may be preceded or succeeded by oxidation and isomerization of the 3β-hydroxy-5-ene structure to a 3-oxo-4-ene by HSD3B7, giving 7α-hydroxycholest-4-en-3-one (7α-HCO) and 7α,12α-dihydroxycholest-4-en-3-one (7α,12α-diHCO), respectively (Figure 8). A general feature of bile acid biosynthesis is that many of the enzymes involved in the pathways accept multiple substrates resulting in variations in the order of reactions depending on the tissue in which they proceed (360). The next steps involve A-ring reductions which may be preceded or succeeded by (25R)26-hydroxylation and (25R)26-carboxylation of cholesterol by CYP27A1 and this and many other steps may proceed extrahepatically (Figure 8). Most of the enzymes involved in the neutral pathway are also involved in the acidic pathway although not in the same order (361). An exception is CYP7A1, which is replaced by CYP7B1 as the 7α-hydroxylase in the acidic pathway. CYP7B1 is expressed in many tissues, not just liver (362, 363), and unlike CYP7A1 uses side-chain oxysterols as its substrate. The acidic pathway mostly generates chenodeoxycholic acid rather than cholic acid, so CYP8B1 has minor involvement. The order of A-ring reduction and side-chain cleavage can be reversed in the acidic pathway with the formation of bile acid intermediates possessing 3-oxo-4-ene or 3β-hydroxy-5-ene functions.

**Steroid Hormone Biosynthesis**

The classical steroid hormones aldosterone (mineralocorticoid), cortisol (glucocorticoid), testosterone (male sex hormone) and 17β-estradiol (female sex hormone) are all formed from...
FIGURE 8 | A simplified view of the major bile acid biosynthesis pathways. The “neutral” pathway (highlighted in blue) starts with 7α-hydroxylation of cholesterol by CYP7A1, the “acidic” pathway with (25R)26-hydroxylation then (25R)26-carboxylation of cholesterol by CYP27A1. In the “acidic” pathway (highlighted in red) CYP7B1 is the 7α-hydroxylase.
cholesterol through multiple oxidation reactions (Figure 9) (364, 365). Pregnenolone formed via CYP11A1 oxidation of cholesterol represents an intermediate between oxysterol and steroid hormone biosynthesis. It is oxidized by HSD3B2 to progesterone on the pathway to aldosterone or by CYP17A1 to 17α-hydroxyprogrenolone on the route to cortisol. Both these pathways use CYP21A2 as a C-21 hydroxylase and CYP11B enzymes as the 11β-hydroxylase. Note, HSD3B1 is the enzyme which generates progesterone from pregnenolone in the placenta, when progesterone acts as the hormone of pregnancy. Further oxidation of 17α-hydroxyprogrenolone by CYP17A1 leads to dehydroepiandrosterone on the road to testosterone and 17β-estradiol. In this pathway additional oxidations and reductions are carried out by HSD3B2 and
HSD17B3, respectively, while CYP19A1 is required to generate estrogens. Besides being synthesized in the adrenal gland and sex organs it is noteworthy that steroids can be synthesized in the brain and are then named neurosteroids (366, 367). A more general term for brain steroids which may be synthesized in the brain or imported from the periphery and exert rapid non-genomic effects is neuroactive steroids. It is beyond the scope of this review to discuss steroid hormone biosynthesis and metabolism in greater detail and the reader is directed to the excellent reviews of Shackleton and colleagues (364, 368–370).

CONCLUDING REMARKS

Enzymatically oxidized lipids are derivatives of PUFA or cholesterol with critical functions in cellular and physiological processes as signaling mediators and hormones. Their biosynthesis is highly regulated and carried out by enzymes that include LOXs, COXs, CYPs, and AKRs. Advances in our understanding of these enzymes have led to the discovery of novel lipid mediators and their biosynthetic routes. Many functional aspects of these enzymes and their products remain unclear, requiring further investigation. These include elucidating the function of 15-LOX-2 (ALOX15B) in macrophages, the regulatory mechanisms of 12-LOXs and eLOX3, the mechanistic details of transcellular biosynthesis, the origin of 18-HEPE required for E-resolvin biosynthesis, the biological functions of orphan CYPs, and the bioactivities/functions of oxygenated endocannabinoids. The relative physiological importance of some multiply oxygenated PUFA mediators, which are generated in extremely low amounts, also needs to be further clarified. This is also true for multiply oxygenated derivatives of cholesterol.

Research on oxygenated PUFA and oxysterols has been carried out largely in parallel, and both areas have benefited greatly from advances in analytical methods. However, there are still major questions to be answered in terms of their proposed roles in human disease including atherosclerosis and neurodegeneration. Here, we presented biosynthetic pathways of oxygenated PUFA and oxysterols, highlighting their (known) functions to show the diversity of products but also to draw connections between the two groups. An integrated approach encompassing the analysis of both lipid groups could be useful in examining the etiology of disease. Despite their involvement in the progression of disease such as atherosclerosis and neurodegenerative disease, the two lipid groups are rarely analyzed together. We propose that oxygenated PUFA and oxysterols are more connected than previously thought, especially as 15-LOX is being increasingly recognized as a regulator of cholesterol metabolism. The immune and nervous systems are both of particular interest as major sites of cholesterol metabolism and 15-LOX expression. Further work on the enzymology of 15-LOX with cholesterol substrates could lead to the discovery of novel oxidized lipids. For example, 15-LOX oxygenation of PUFA esters of oxysterols could generate novel lipids that link both classes directly in cell types that possess the enzymatic machinery for oxysterol and oxylipin biosyntheses (e.g., macrophages). An alternative biosynthetic route could be through the esterification of oxylipins with free oxysterols. That said, the detection of these proposed molecules could be challenging due to low abundance and sensitivity to alkaline conditions commonly used in analysis. Finally, the substrate promiscuity of many of the enzymes involved in production of oxidized lipids provides a technical challenge for dissection of (patho)physiological function of specific oxidized lipids. Clearly, there is plenty of scope for ongoing exploration of the molecular, cellular, and physiological functions of oxidized lipids.

AUTHOR CONTRIBUTIONS

AH planned the manuscript. AH, WG, and YW wrote the manuscript with input from AF and VO. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

AAH acknowledges funding from Kuwait University and support from the Kuwait Cultural Office (KCO) in London. Work in Swansea was supported by the UK Biotechnology and Biological Sciences Research Council (BBRSC, grant numbers BB/N015932/1 to WJG and BB/L001942/1 to YW). AJF is supported by funding from Barts Charity. VBO is a Royal Society Wolfson Merit Award Holder and acknowledges funding from the Wellcome Trust for LIPID MAPS (203014/Z/16/Z).

REFERENCES

1. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest (2001) 108(1):15–23. doi: 10.1172/JCI13416
2. Slatter DA, Percy CL, Allen-Redpath K, Gajsiewicz JM, Brooks NJ, Clayton A, et al. Enzymatically oxidized phospholipids restore thrombin generation in coagulation factor deficiencies. JCI Insight (2018) 3(6):e98459. doi: 10.1172/jci.insight.98459
3. Buckley CD, Gilroy DW, Serhan CN. Resolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity (2014) 40 (3):315–27. doi: 10.1016/j.immuni.2014.02.009
4. Choi SH, Sviridov D, Miller YI. Oxidized cholesteryl esters and inflammation. Biochim Biophys Acta Mol Cell Biol Lipids (2017) 1862 (4):393–7. doi: 10.1016/j.bbalip.2016.06.020
5. Lauder SN, Allen-Redpath K, Slatter DA, Aldrovandi M, O’Connor A, Farewell D, et al. Networks of enzymatically oxidized membrane lipids support calcium-dependent coagulation factor binding to maintain hemostasis. Sci Signal (2017) 10(507):eaan2787. doi: 10.1126/scisignal.aan2787
6. Stachenfeld NS. Sex hormone effects on body fluid regulation. Exerc Sport Sci Rev (2008) 36(3):152–9. doi: 10.1097/JES.0b013e31817be928
7. Kuo T, McQueen A, Chen TC, Wang JC. Regulation of Glucose Homeostasis by Glucocorticoids. Adv Exp Med Biol (2015) 872:99–126. doi: 10.1007/978-1-4939-2895-8_5
20. Funk CD, Funk LB, FitzGerald GA, Samuelsson B. Characterization of 5-lipoxygenase expression in dendritic cells generated from CD34(+) hematopoietic progenitors and in lymphoid organs. Proc Natl Acad Sci U S A (1997) 94(12):6148–52. doi: 10.1073/pnas.94.12.6148

21. Kutzner L, Goloshchapova K, Heydeck D, Stehling S, Kuhn H, Schebb NH. Characterization of Differential Dynamics, Specificity, and Allostery of Lipoygenase Family Members. J Chem Inf Model (2019) 59(5):2496–508. doi: 10.1021/acs.jcim.9b00006

22. Weisinger G, Graff-Cohen M, Hirsh M, Knoll E, Sharon O, Many A, et al. 12S-Lipoxygenase is necessary for human vascular smooth muscle cell survival. Exp Cell Res (2013) 319(10):1586–93. doi: 10.1016/j.yexcr.2013.04.001

23. Boeglin WE, Kim RB, Brash AR. A 12R-lipoxygenase in human skin: mechanistic evidence, molecular cloning, and expression. Proc Natl Acad Sci U S A. (1998) 95(12):6744–9. doi: 10.1073/pnas.95.12.6744

24. Sun D, McDonnell M, Chen XS, Lakkis MM, Li H, Isaacs SN, et al. Human 12(R)-lipoxygenase and the mouse ortholog. Molecular cloning, expression, and gene chromosomal assignment. J Biol Chem (1998) 273(30):33540–7. doi: 10.1074/jbc.273.30.33540

25. Zheng Y, Yin H, Boeglin WE, Elias PM, Crumrine D, Beier DR, et al. Lipoygenases mediate the effect of essential fatty acid in skin barrier formation: a proposed role in releasing omega-hydroxyeramide for construction of the corneocyte lipid envelope. J Biol Chem (2011) 286(27):24066–56. doi: 10.1074/jbc.M111.251496

26. Schneider C, Kenney DS, Boeglin WE, Brash AR. Detection and cellular localization of 12R-lipoxygenase in human tonsils. Arch Biochem Biophys (2001) 386(2):268–74. doi: 10.1006/abbi.2000.2217

27. Garcia-Verduco I, BenMohamed F, Tattermusch S, Leduc D, Charpigny G, Chignard M, et al. A role for 12R-lipoxygenase in MUC5AC expression by respiratory epithelial cells. Eur Respir J (2012) 40(3):714–23. doi: 10.1183/09031936.0023111

28. West SJ, Crucet M, Gempere C, Loretz C, Hersberger M. Expression and regulation of 12/15-lipoxygenases in human primary macrophages. Atherosclerosis (2012) 225(1):121–7. doi: 10.1016/j.atherosclerosis.2012.07.022

29. Turk J, Maas RL, Kohler A, Muller A, Zintel F, Kuhn H, et al. IL-4 determines eosinoid formation in dendritic cells by down-regulation of 5-lipoxygenase and up-regulation of 15-lipoxygenase 1 expression. Proc Natl Acad Sci U S A. (2001) 98(5):3572–5. doi: 10.1073/pnas.98.21.3572

30. Spanbroek R, Hildner M, Kohler A, Muller A, Zintel F, Kuhn H, et al. IL-4 determines eosinoid formation in dendritic cells by down-regulation of 5-lipoxygenase and up-regulation of 15-lipoxygenase 1 expression. Proc Natl Acad Sci U S A. (1997) 94(12):6148–52. doi: 10.1073/pnas.94.12.6148

31. Matsumoto T, Funk CD, Radmark O, Hoog JO, Jornvall H, Samuelsson B. Molecular cloning and amino acid sequence of human 5-lipoxygenase. Proc Natl Acad Sci U S A (1988) 85(1):26–30. doi: 10.1073/pnas.85.1.26

32. Colomorea T, Di Paola R, Macchia F, Guerriero MC, Tursi A, Butterfield JH, et al. 5-Lipoxygenase upregulation by dexamethasone in human mast cells. Biochimie Bios Phys Res Commun (1999) 265(3):617–24. doi: 10.1006/ j.brc.1999.1732

33. Spanbroek R, Hildner M, Steinhibler D, Fusenig N, Yoneda K, Radmark O, et al. 5-lipoxygenase expression in dendritic cells generated from CD34(+) hematopoietic progenitors and in lymphoid organs. Blood (2000) 96(12):3857–65. doi: 10.1182/blood.V96.12.3857

34. Krieg P, Marks F, Furstenberger G. A gene cluster encoding human epidermis-type lipoxygenases at chromosome 17p13.1: cloning, physical mapping, and expression. Genomics (2001) 73(3):323–30. doi: 10.1006/geno.2001.6519

35. Zheng Y, Brash AR. Dioxigenase activity of epidermal lipoygenase-3 unveiled: typical and atypical features of its catalytic activity with natural and synthetic polyunsaturated fatty acids. J Biol Chem (2010) 285(1):39866–75. doi: 10.1074/jbc.M110.153374

36. Uniprot C. Uniprot: a worldwide hub of protein knowledge. Nucleic Acids Res (2019) 47(D1):D506–D15. doi: 10.1093/nar/gky1049

37. Choi J, Chon JK, Kim S, Shin W. Conformational flexibility in mammalian 15S-lipoxygenase: Reinterpretation of the crystallographic data. Proteins (2008) 70(3):1023–32. doi: 10.1002/prot.21590

38. Gilbert NC, Bartlett SG, Waight MT, Neau DB, Boeglin WE, Brash AR, et al. The structure of human 5-lipoxygenase. Science (2011) 331(6014):217–9. doi: 10.1126/science.1197203

39. Koe MJ, Neau DB, Mitchell CE, Bartlett SG, Newcombe ME. The structure of human 15-lipoxygenase-2 with a substrate mimic. J Biol Chem (2014) 289(12):8356–9. doi: 10.1074/jbc.M113.473777

40. Walthier M, Anton M, Wiedmann M, Fletterick R, Kuhn H. The N-terminal domain of the reticulocyte-type 15-lipoxygenase is not essential for enzymatic activity but contains determinants for membrane binding. J Biol Chem (2002) 277(30):27360–6. doi: 10.1074/jbc.M203234200

41. Walthier M, Hofheinz K, Vogel R, Roffeis J, Kuhn H. The N-terminal barrel domain of mammalian lipoygenases including mouse 5-lipoxygenase is not essential for catalytic activity and membrane binding but exhibits regulatory functions. Arch Biochem Biophys (2011) 516(1):1–9. doi: 10.1016/j.abb.2011.09.004

42. Hammarberg T, Provost P, Persson B, Radmark O. The N-terminal domain of 5-lipoxygenase binds calcium and mediates calcium stimulation of enzyme activity. J Biol Chem (2000) 275(49):38787–93. doi: 10.1074/jbc.M006136200
46. Chen XS, Funk CD. The N-terminal “beta-barrel” domain of 5-lipoxygenase is essential for nuclear membrane translocation. *J Biol Chem* (2001) 276(11):9111–9. doi: 10.1074/jbc.M009203200

47. Brinckmann R, Schnurr K, Heydeck D, Rosenbach T, Kolde G, Khan H. Membrane Translocation of 15-Lipoxygenase in Hematopoietic Cells Is Calcium-Dependent and Activates the Oxygenase Activity of the Enzyme. *Blood* (1998) 91(1):64–74. doi: 10.1182/blood.V91.1.64

48. Bender G, Schexnaydre EE, Murphy RC, Uhison C, Newcomer ME. Membrane-dependent Activities of Human 15-LOX-2 and Its Murine Counterpart: IMPLICATIONS FOR MURINE MODELS OF Atherosclerosis. *J Biol Chem* (2016) 291(37):19413–24. doi: 10.1074/jbc.M116.741454

49. Basavarajappa D, Wan M, Lukic A, Steinhalber D, Samuelssohn B, Radmark O. Roles of coactosin-like protein (CLP) and 5-lipoxygenase-activating protein (FLAP) in cellular leukotriene biosynthesis. *Proc Natl Acad Sci U S A* (2014) 111(31):11371–6. doi: 10.1073/pnas.1410983111

50. Hafner AK, Cernescu M, Hofmann B, Ermisch M, Hornig M, Metzner J, Siebert M, Krieg P, Lehmann WD, Marks F, Furstenberger G. Enzymic activity and protein phosphorylation in inflammation and cell death. *Oxid Med Cell Longev* (2019) 2019:2749173. doi: 10.1155/2019/2749173

51. Luo M, Jones SM, Peters-Golden M, Brock TG. Nuclear localization of 5-lipoxygenase is essential for nuclear membrane translocation. *J Biol Chem* (2012) 80(3):703–12. doi: 10.1074/jbc.M111.304521

52. Sun QY, Zhou HH, Mao XY. Emerging Roles of 5-Lipoxygenase by Amino Acid Side Chains within a Gas Migration Unit. *FEBS Lett* (2017) 586(1):149–55. doi: 10.1016/j.febslet.2017.07.073

53. Yu Z, Schneider C, Boeglin WE, Marnett LJ, Brash AR. The lipoxygenase gene ALOXE3 implicated in skin differentiation encodes a hydroperoxide isomerase. *Proc Natl Acad Sci U S A* (2003) 100(16):9162–7. doi: 10.1073/pnas.83.12.4175

54. Rouzer CA, Matsumoto T, Samuelssohn B. Single protein from human leukocytes possesses 5-lipoxygenase and leukotriene A4 synthase activities. *Proc Natl Acad Sci U S A* (1986) 83(4):857–61. doi: 10.1073/pnas.83.4.857

55. Shizimu T, Izumi T, Seyama Y, Tadokoro K, Radmark O, Samuelssohn B. Characterization of leukotriene A4 synthase from murine mast cells: evidence for its identity to arachidonate 5-lipoxygenase. *Proc Natl Acad Sci U S A* (1986) 83(12):4175–9. doi: 10.1073/pnas.83.12.4175

56. Ueda N, Yamamoto S, Oates JA, Brash AR. Stereoselective hydrogen abstraction in leukotriene A4 synthesis by purified 5-lipoxygenase of porcine leukocytes. *Prostaglandins* (1986) 32(1):34–8. doi: 10.1016/0090-6980(86)90141-3

57. MacMillan DK, Hill E, Sala A, Sigal E, Shuman T, Henson PM, et al. Eosinophil 15-lipoxygenase is a leukotriene A4 synthase. *J Biol Chem* (1994) 269(3):2666–9.

58. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatetraenes and 17R-resolvins generated from docosahexaenoic acid in murine brain, murine blood, and glial cells. Autoxidation in anti-inflammation. *J Biol Chem* (2003) 278(17):16777–83. doi: 10.1074/jbc.M300218200

59. Kuhn H, Wiesner R, Stender H, Schewe T, Lankin VZ, Nekrasov A, et al. Requirement of monohydroperoxy fatty acids for the oxygenation of 15LS-HETE by reticulocyte lipoxygenase. *FEBS Lett* (2006) 526(2):247–52. doi: 10.1016/j.febslet.2005.08.075

60. Lepley RA, Fitzpatrick FA. Irreversible inactivation of 5-lipoxygenase by leukotriene A4. Characterization of product inactivation with purified enzyme and intact leukocytes. *J Biol Chem* (1994) 269(4):2627–31.

61. Wiesner R, Suzuki H, Walthier M, Yamamoto S, Kuhn H. Suicidal inactivation of the rabbit 15-lipoxygenase by 15S-HpETE is paralleled by covalent modification of active site peptides. *Free Radical Biol Med* (2003) 34(3):304–15. doi: 10.1016/S0891-5849(02)01244-3

62. Kohli P, Levy BD. Resolvins and protectins: mediating solutions to inflammation. *Br J Pharmacol* (2009) 158(4):960–71. doi: 10.1111/j.1476-5381.2009.00290.x

63. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, et al. Resolvins and protectins: resolvins are endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. *Proc Natl Acad Sci U S A.* (2005) 102(21):7671–6. doi: 10.1073/pnas.040271102

64. Forsell PK, Brunström A, Johannesson M, Claesson HE. Metabolism of anandamide into eicosanoids by 15-lipoxygenase-1 and glutathione transferases. *Lipids* (2012) 47(8):781–91. doi: 10.1177/0024300012458540

65. Kim HY, Spector AA. Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid in murine brain, murine blood, and glial cells. Autoxidation in anti-inflammation. *J Biol Chem* (2003) 278(17):16777–83. doi: 10.1074/jbc.M300218200

66. Mathew T, Kanner D, Kanner AS, Johnson CR, Spector AA. 15-Lipoxygenase-independent generation of epoxygenated metabolites of docosahexaenoic acid. *FEBS Lett* (2004) 550(1–3):52–8. doi: 10.1016/j.febslet.2004.04.015

67. Hafner AK, Brash AR. The 15-lipoxygenase-1 gene is essential for nuclear membrane translocation. *J Biol Chem* (2012) 287(19):15579–84. doi: 10.1074/jbc.M111.257271

68. Schwartz K, Walthier M, Anton M, Gerth C, Feussner I, Kuhn H. Structural basis for lipoxygenase specificity. Conversion of the human leukocyte 5-lipoxygenase to a 15-lipoxygenating enzyme species by site-directed mutagenesis. *J Biol Chem* (2001) 276(1):773–9. doi: 10.1074/jbc.M005114200

69. Brash AR. The structural basis for specificity in lipoxygenase catalysis. *Protein Sci* (2015) 24(3):298–309. doi: 10.1002/pro.2626

70. Amakau T, Batteur S, Pagani S, Fabris T, Brash AR. The 15-lipoxygenase-1 gene and oxylipins in inflammation and cell death. *Frontiers in Endocrinology* (2011) 2:19. doi: 10.3389/fendo.2011.00019

71. Collazo L, Klinman JP. Control of the Position of Oxygen Delivery in Soybean Lipoxygenase-1 by Amino Acid Side Chains within a Gas Migration Channel. *J Biol Chem* (2016) 291(17):9052–9. doi: 10.1074/jbc.M115.709154
100. Grosser T, Fries S, Barrett J, Sigal E, Kuhn H. Oxidation of lipoproteins by mammalian lipoxigenases. *Eur J Biochem* (1993) 213 (2):413-20. doi:10.1111/j.1432-1033.1993.tb17755.x

101. Monastersky R. The heart of it. *Nature* (2015) 520(7547):444-5. doi:10.1038/420444a

102. Hla T, Neilson K. Human cyclooxygenase-2 DNA. *Proc Natl Acad Sci U S A* (1992) 89(16):7384–8. doi:10.1073/pnas.89.16.7384

103. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. *FEBS Lett* (1993) 330(2):156–60. doi:10.1016/0014-5793(93)80626-3

104. Pablos JL, Santiago B, Carreira PE, Galindo M, Gomez-Reino JJ. Cyclooxygenase-1 and -2 are expressed by human T cells. *Clin Exp Immunol* (1999) 115(1):86–90. doi:10.1111/j.1365-2499.1999.00780.x

105. Zidar N, Oder K, Glavic D, Jerse M, Zupanc T, Stajer D. Cyclooxygenase in normal human tissues—is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? *J Cell Mol Med* (2009) 13(9B):3753–63. doi:10.1111/j.1566-3424.2008.00430.x

106. Ryan EP, Pollack SJ, Murant TL, Bernstein SH, Felgar RE, Phipps RP. Activated Human B Lymphocytes Express Cyclooxygenase-2 and Cyclooxygenase Inhibitors Attenuate Ab Production. *J Immunol* (2005) 174(8):5134–2. doi:10.4049/jimmunol.174.8.5134-a

107. Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. *Nature* (1994) 376(6540):89–93. doi:10.1038/37689

108. Rajkumar V, Prasad NA, Garg M, Saini SK, Prasad RS, Stastny C. Cyclooxygenase-2 expression in human coronary artery smooth muscle cells. *J Biol Chem* (2003) 278(46):45763–7. doi:10.1074/jbc.M026385

109. Lionson R, Krangel M, Fang Z, Cao Y, Fang J, Inselman B, et al. Human cyclooxygenase-2 is expressed in keratinocytes and B lymphocytes. *J Biol Chem* (2000) 275(51):40844–51. doi:10.1074/jbc.M008350200

110. Ferrer E, Garcia-Vaz E, Jiao J, Berglund LM, et al. Cyclooxygenase-2 expression pattern reveals non-vascular sites of COX-2 expression. *Arterioscler Thromb Vasc Biol* (2003) 23(9):1747–52. doi:10.1161/01.ATV.0000078053.15386.3b

111. Rouzer CA, Bernlohr DA, Jiang H, Dean J, Renedo J, Walz TL, et al. Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding Network. *Biochemistry* (2010) 49(33):7069–79. doi:10.1021/bi1002398

112. Kirkby NS, Chan MV, Zaiss AK, Garcia-Vaz E, Jiao J, Berglund LM, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. *Nature* (1996) 384(6610):644–8. doi:10.1038/384644a0

113. Beier NW, Hoyer LW, Johnstone SR, Wiegandt M, Day AD, Menon SK, et al. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. *J Biol Chem* (2003) 278(46):45763–79. doi:10.1074/jbc.M026799

114. Kirkby NS, Zaiss AK, Urquhart P, Jiao J, Austin PJ, Al-Yamani M, et al. LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression. *PloS One* (2014) 9(7):e102362. doi:10.1371/journal.pone.0102362

115. Orlando BJ, Malkowski MG. The structural basis of endocannabinoid oxygenation by cyclooxygenase-2. *J Biol Chem* (2011) 286(23):20736–45. doi:10.1074/jbc.M111.230367

116. Xu S, Hermanson DJ, Banerjee S, Ghebreselasie K, Clayton GM, Garavito RM, et al. Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding Network. *J Biol Chem* (2014) 289(10):6799–808. doi:10.1074/jbc.M113.517987

117. Lucido MJ, Orlando BJ, Vecchio AJ, Malkowski MG. Crystal Structure of Aspirin-Acetylated Human Cyclooxygenase-2: Insight into the Formation of Products with Reversed Stereoreactivity. *Biochemistry* (2016) 55(8):1226–38. doi:10.1021/acs.biochem.5b00359

118. Orlando BJ, Malkowski MG. Substrate-selective Inhibition of Cyclooxygenase-2 by Fenamic Acid Derivatives Is Dependent on Peroxide Tone. *J Biol Chem* (2016) 291(29):15069–81. doi:10.1074/jbc.M116.725713

119. Xiao G, Chen W, Kulmacz RJ. Comparison of structural stabilities of prostaglandin H synthase-1 and -2. *J Biol Chem* (1998) 273(12):6801–11. doi:10.1074/jbc.273.12.6801

120. Michael Garavito R, Malkowski MG, DeWitt DL. The structures of prostaglandin endoperoxide H synthases-1 and -2. *Prostaglandins Other Lipid Mediators* (2002) 68-69:129–52. doi:10.1016/S0002-8673(02)00006-6

121. Spencer AG, Woods JW, Arakawa T, Singer II, Smith WL. Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy. *J Biol Chem* (1998) 273(16):9886–93. doi:10.1074/jbc.273.16.9886

122. Yuan C, Smith WL. A cyclooxygenase-2-dependent prostaglandin E2 biosynthetic system in the Golgi apparatus. *J Biol Chem* (2015) 290(9):5606–20. doi:10.1074/jbc.M114.632463

123. Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights. *J Lipid Res* (2009) 50 Suppl(Suppl):S29–34. doi:10.1194/jlr.R800042-JLR200

124. Otto JC, DeWitt DL, Smith WL. N-glycosylation of prostaglandin endoperoxide synthases-1 and -2 and their orientations in the endoplasmic reticulum. *J Biol Chem* (1999) 274(24):18324–42

125. Sevigny MB, Li CF, Alas M, Hughes-Fulford M. Glycosylation regulates turnover of cyclooxygenase-2. *FEBS Lett* (2006) 580(28-29):6533–6. doi:10.1016/j.febslet.2006.07.073
160. Srejber M, Navratilova V, Paloncýova M, Bazgier V, Berka K, Anzenbacher P, et al. Membrane-attached mammalian cytochrome P450: An overview of the membrane's effects on structure, drug binding, and interactions with redox partners. *J Orgn Biochem* (2018) 183:117–36. doi: 10.1016/j.jorgbio.2018.03.002

161. Erickson SK, Bosterling B. Cholesterol 7 alpha-hydroxylase from human liver: partial purification and reconstruction into defined phospholipid-cholesterol vesicles. *J Lipid Res* (1981) 22(5):872–6.

162. Loep J, Descatoire V, Maurice M, Beaune P, Belghiti J, Housin D, et al. Cytochromes P-450 in human hepatocyte plasma membrane: Recognition by several autoantibodies. *Gastroenterology* (1993) 104(1):203–16. doi: 10.1016/0016-5085(93)90853-5

163. Neve EP, Ingelman-Sundberg M. Molecular basis for the transport of cytochrome P450 2E1 to the plasma membrane. *J Biol Chem* (2000) 275(22):17130–5. doi: 10.1074/jbc.M000575200

164. Leung YK, Lau KM, Mobjle J, Jiang Z, Ho SM. Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. *Cancer Res* (2005) 65(9):3726–34. doi: 10.1158/0008-5472.CAN-04-3771

165. Li D, Tolleson WH, Yu D, Chen S, Guo L, Xiao W, et al. Regulation of cytochrome P450 expression by microRNAs and non-long coding RNAs: Epigenetic mechanisms in environmental toxicology and carcinogenesis. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rep* (2019) 37(3):180–214. doi: 10.1080/15590501.2019.1639481

166. Nelson NR, Nebert DW. Cytochrome P450 (CYP) Gene Superfamily. eLS. Chichester: John Wiley & Sons, Ltd (Ed (2018) p. 1–22.

167. Williams PA, Cosme J, Sridhar V, Johnson EF, McRee DE. Mammalian microsomal cytochrome P450 monoxygenase: structural adaptations for membrane binding and functional diversity. *Mol Cell* (2000) 5(1):121–31. doi: 10.1016/s1097-2651(99)00808-6

168. Annalora AJ, Goodin DB, Hong WX, Zhang Q, Johnson EF, Stout CD. Complex formation in vesicle-membrane cytochrome P450 monooxygenase: structural adaptations for living cells. *Biochemistry* (1999) 38(29):9456–61. doi: 10.1021/bi990584l

169. Schwarz D, Chernogolov A, Kisselev P. Functional interactions in cytochrome P450 systems (CYP1A1 and CYP1B1) as evidenced by rotational diffusion experiments using EPR and ST-EPR. *Biochemistry* (1999) 38(29):9456–61. doi: 10.1021/bi990584l

170. Szczesna-Skorupa E, Mallah B, Kemper B. Fluorescence resonance energy transfer analysis of cytochromes P450 2C2 and 2E1 molecular interactions in living cells. *J Biol Chem* (2003) 278(13):13399–406. doi: 10.1074/jbc.M300969200

171. Hsu MH, Baer BR, Rettie AE, Johnson EF. The Crystal Structure of Cytochrome P450 4B1 (CYP4B1) Monooxygenase Complexed with its Substrate Octane Discloses Several Structural Adaptations for omega-Hydroxylation. *J Biol Chem* (2010) 285(43):32720–33. doi: 10.1074/jbc.M110.118406

172. Hecker M, Ulrich V. On the mechanism of prostacyclin and thromboxane A2 biosynthesis. *J Biol Chem* (1989) 264(1):141–50.

173. Cook DJ, Finnigan JD, Cook K, Black GW, Charnock SJ. Chapter Five - Cytochromes P450: History, Classes, Catalytic Mechanism, and Industrial Application. In: CZ Christov, editor. *Advances in Protein Chemistry and Structural Biology*. Academic Press (2016). p. 105–26. doi: 10.1016/bapcb.2016.07.003

174. Lamb DC, Waterman MR. Unusual properties of the cytochrome P450 superfamily. *Philos Trans B Societ B Biol Sci* (2013) 368(1612):20120434. doi: 10.1098/rstb.2012.0343

175. Barbosa-Sicard E, Markovic M, Honeck H, Christ B, Muller DN, Schunk WH. Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2F2 subfamily. *Biochem Biophys Res Commun* (2005) 329(4):1275–81. doi: 10.1016/j.bbrc.2005.02.103

176. Arnold C, Markovic M, Blossey K, Wallukat G, Fischer R, Dechend R, et al. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of omega-3 fatty acids. *J Biol Chem* (2010) 285(43):32720–33. doi: 10.1074/jbc.M110.118406

177. Honda A, Miyazaki T, Ikegami T, Iwamoto J, Maeda T, Hirayama T, et al. Cholesterol 25-hydroxylation activity of CYP3A. *J Lipid Res* (2011) 52(8):1509–16. doi: 10.1194/jlr.M014084

178. Griffiths WJ, Crick PJ, Meljon A, Theofilopoulos S, Abdel-Khalik J, Yutuc E, et al. Additional pathways of sterol metabolism: Evidence from analysis of Cyp27a1−/− mouse brain and plasma. *Biochim Biophys Acta Mol Cell Biol Lipids* (2019) 1864(2):191–211. doi: 10.1016/j.bbalip.2018.11.006

179. Bodin K, Andersson U, Rydstedt E, Ellis E, Notlin M, Pikuška I, et al. Metabolism of 4 beta -hydroxycholesterol in humans. *J Biol Chem* (2002) 277(35):31354–40. doi: 10.1074/jbc.M10712200

180. Kawashima H, Naganuma T, Kusunose E, Kono T, Yasmoto R, Sugimura K, et al. Human fatty acid omega-hydroxylase, CYP4A11: determination of complete genomic sequence and characterization of purified recombinant protein. *Arch Biochem Biophys* (2000) 378(2):333–9. doi: 10.1006/abbi.2000.1831

181. Shinoy K, Xu L, Tallman KA, Cheng Q, Porter NA, Guengerich FP. Conversion of 7-dehydrocholesterol to 7-ketocholesterol is catalyzed by human cytochrome P450 7A1 and occurs by direct oxidation without an epoxide intermediate. *J Biol Chem* (2011) 286(38):33021–8. doi: 10.1074/jbc.M111.282434

182. Björkhem I, Diczfalusy U, Lovgren-Sandblom A, Starck L, Jonsson M, Tallman K, et al. On the formation of 7-ketocholesterol from 7-dehydrocholesterol in patients with CTX and SLO. *J Lipid Res* (2014) 55(6):1165–72. doi: 10.1194/jlr.P048603

183. Schwarz M, Lund EG, Lathke R, Björkhem I, Russell DW. Identification and characterization of a mouse oxidyster alpha-hydroxylase CDN4. *J Biol Chem* (1997) 272(38):23995–4001. doi: 10.1074/jbc.272.38.23995

184. Gafvels M, Olin M, Chowdhary BP, Raussepp T, Andersson U, Persson B, et al. Structure and chromosomal assignment of the sterol 12alpha-hydroxylase gene (CYP8B1) in human and mouse: eukaryotic cytochrome P-450 gene devoid of introns. *Genomics* (1999) 56(2):184–96. doi: 10.1006/geno.1998.5606
197. Pikuleva IA. Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos (2006) 34(4):513–20. doi: 10.1124/dmd.105.008789

198. Coudier CL, Jaffe RR. Functional maturation of the primate fetal adrenal in vivo. 3. Specific zonal localization and developmental regulation of CYP21A2 (P450c21) and CYP11B1/CYP11B2 (P450c11/aldoosterone synthe

199. Payne AH, Hales DB. Overview of steroidalogen enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev (2004) 25(6):947–70. doi: 10.1210/er.2003-0030

200. Omdahl JL, Morris HA, May BK. Hydroxylase enzymes of the vitamin D–dependent calcium-regulating system: the story of sterol 27-hydroxylase. J Biol Chem (2008) 283(28):19647–57. doi: 10.1074/jbc.M108.589144

201. Shyadehi AZ, Lamb DC, Kelly SL, Kelly DE, Schunck WH, Wright JN, et al. The mechanism of the acyl-carbon bond cleavage reaction catalyzed by recombinant sterol 14 alpha-demethylase of Candida albicans (other names are: lanosterol 14 alpha-demethylase, P-45014DM, and CYP51). J Biol Chem (1996) 271(21):12445–50. doi: 10.1074/jbc.271.21.12445

202. Shunskевич N, MacKenzie F, Cherkesova T, Grabovei I, Usanov S, Park HW. Structural basis for pregnenolone biosynthesis by the mitochondrial monooxygenase system. Proc Natl Acad Sci U S A (2011) 108(25):10139–43. doi: 10.1073/pnas.101944108

203. Griffiths WJ, Wang Y. Oxysterols as lipid mediators: Their biosynthetic genes, enzymes and metabolites. Prostaglandins Other Lipid Med (2020) 147:106381. doi: 10.1016/j.prostaglandins.2019.106381

204. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem (2003) 72:137–74. doi: 10.1146/annurev.biochem.72.121801.161712

205. Cali JJ, Russell DW. Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P450 that catalyzes multiple oxidation reaction in bile acid biosynthesis. J Biol Chem (1991) 266(12):7774–8

206. Lund EG, Guileyardo JM, Russell DW. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci U S A (1999) 96(13):7238–43. doi: 10.1073/pnas.96.13.7238

207. Mast N, Norcross R, Andersson U, Shou M, Nakayama K, Bjorkhem I, et al. Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry (2003) 42(48):14824–92. doi: 10.1021/bi035312f

208. Bodin K, Andersson U, Rydstedt E, Ellis E, Norlin M, Pikuleva I, et al. Metabolism of 4 beta-hydroxysterols in humans. J Biol Chem (2002) 277(35):31534–40. doi: 10.1074/jbc.M201712200

209. Tuckey RC, Cameron KJ. Side-chain specificities of human and bovine cytochromes P-450. Eur J Biochem (1993) 217(1):209–15. doi: 10.1111/j.1432-1033.1993.tb18235.x

210. Petrunak EM, DeVore NM, Porubsky PR, Scott EE. Structures of human steroidal cytochrome P450 17A1 with substrates. J Biol Chem (2014) 289(47):32952–64. doi: 10.1074/jbc.M114.610998

211. Heals NT, Ireland LS, Harrison DJ, Hayes JD. Major differences exist in the expression of human a- and b-subunit genes and protein levels. Biochem J (2003) 375(3):415–20. doi: 10.1042/0006-2952(2003)0375-0341-034105

212. Byrns MC. Role of aldo-keto reductase enzymes in mediating the timing of parturition. Front Pharmacol (2012) 3:53. doi: 10.3389/fphar.2012.00058

213. Endo S, Matsuura T, Mamiya H, Ohta C, Suda M, Kitade Y, et al. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids. Arch Biochem Biophys (2009) 487(1):1–9. doi: 10.1016/j.abb.2009.05.009

214. Ruiz FX, Porte S, Pares X, Fares J. Biological role of aldose-reductase in retinoid acid biosynthesis and signaling. Front Pharmacol (2012) 3:58. doi: 10.3389/fphar.2012.00058

215. Barski OA, Tipparaju SM, Bhagatnar A. The aldose reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev (2008) 40(4):533–624. doi: 10.1080/03602530802341349

216. Weber S, Salabei JK, Moller G, Kremmer E, Bhagatnar A, Adamski J, et al. Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldose reductase with activity towards steroids and 3-keto-acyl-CoA conjugates. J Biol Chem (2015) 290(10):6531–45. doi: 10.1074/jbc.M114.610121

217. Byrns MC. Role of aldose-reductase enzymes in mediating the timing of parturition. Front Pharmacol (2011) 2:92. doi: 10.3389/fphar.2011.00092
Hajeyah et al. Biosynthesis of Oxidized Lipids

238. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, et al. Human 3α,5α-dihydroxysteroid dehydrogenase isozymes isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. *Biochem J* (2000) 351(Pt 1):67–77. doi: 10.1042/0242-6021:3510067

239. Burczynski ME, Srihdar GR, Palacak NT, Penning TM. The reactive oxygen species–and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the alpha,beta-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonenone. *J Biol Chem* (2001) 276(4):2890–7. doi: 10.1074/jbc.M006553020

240. Lyon RC, Li D, McGarvie G, Ellis EM. Aldo-keto reductases mediate constitutive and inducible protection against aldehyde toxicity in human neuroblastoma SH-SYSY cells. *Neurochem Int* (2003) 42(1):113–21. doi: 10.1006/neuint.2002.10.007

241. Suzuki-Yamamoto T, Nishizawa M, Fukui M, Okuda-Ashitaka E, Nakajima T, Ito S, et al. cDNA cloning, expression and characterization of human prostaglandin F synthase. *FEBS Lett* (1999) 462(3):335–40. doi: 10.1016/s0014-5793(99)01551-3

242. Penning TM. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review. *J Mol Endocrinol* (2002) 36(6 Pt 1):1081–1090. doi: 10.1530/jme.0.02606

243. Penning TM. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review. *Expert Opin Ther Pat* (2017) 27(12):1329–40. doi: 10.1080/13543776.2017.1379503

244. Chen M, Drury JE, Penning TM. Aldo-keto reductase using sequence and structural homologies. *Frontiers in Endocrinology* | www.frontiersin.org November 2020 | Volume 11 | Article 591819 29

245. Matsunaga T, Haga M, Watanabe G, Shinoda Y, Endo S, Kajiwara Y, et al. 9,10-Phenanthrenequinone promotes secretion of pulmonary aldo-keto reductases with surfactant. *Cell Tissue Res* (2012) 347(2):407–17. doi: 10.1007/s00441-011-1394-5

246. Luo DX, Huang MC, Ma J, Gao Z, Liao DF, Cao D. Aldo-keto reductase family I, member B10 is secreted through a lysosome-mediated non-classical pathway. *Biochem J* (2011) 438(1):71–80. doi: 10.1042/BJ20110111

247. Kelly VP, Sherratt PJ, Crouch DH, Hayes JD. Novel homodimeric and heterodimeric rat gamma-hydroxybutyrate synthases that associate with the Golgi apparatus define a distinct subclass of aldo-keto reductase 7 family proteins. *Biochem J* (2002) 366(Pt 3):847–61. doi: 10.1042/BJ20020342

248. Penning TM, Wangtrakuldee P, Auchs R. Structural and Functional Biology of Aldo-Keto Reductase Steroid-Transforming Enzymes. *Endocrin Rev* (2019) 40(2):447–75. doi: 10.1201/ev.2018-00089

249. Ma H, Penning TM. Conversion of mammalian 3α-hydroxysteroid dehydrogenase to 20α-hydroxysteroid dehydrogenase using loop chimeras: changing specificity from androgens to progesterins. *Proc Natl Acad Sci U S A* (1999) 96(20):11161–6. doi: 10.1073/pnas.96.20.11161

250. Gullib JM, Mann S, MacKinnon R. Structure of a voltage-dependent K+ channel beta subunit. *Cell* (1999) 97(7):943–52. doi: 10.1016/s0009-2807(00)00249-8

251. Di Luccio E, Elling RA, Wilson DJ. Identification of a novel NADH-specific aldo-keto reductase using sequence and structural homologies. *Biochem (2006)* (400)1:105–14. doi: 10.1021/bi0606600

252. Jez JM, Bennett MJ, Schlegel BP, Lewis M, Penning TM. Comparative anatomy of the aldo-keto reductase superfamily. *Biochem J* (1997) 326Pt 3(Pt 3):625–36. doi: 10.1042/BJ3260625

253. Liu SQ, Jin H, Zacarias A, Srivastava S, Bhatnagar A. Binding of pyridine nucleotides to the beta-subunit of the voltage sensitive potassium channels. *J Biol Chem* (2001) 130-132(1-3):955–62. doi: 10.1002/1097-2797(00)00249-8

254. Ireland LS, Harrison DJ, Neal GE, Hayes JD. Molecular cloning, expression and characterization of human steroid 5beta-reductase (AKR1D1). *Stereoids* (2011) 76(5):484–90. doi: 10.1016/j.steroids.2011.01.003

255. Knight LP, Primiano T, Groopman JD, Kessler TW, Sutter TR. cDNA cloning, expression and activity of a second human aflatoxin B1-metabolizing member of the aldo-keto reductase superfamily, AKR7A3. *Carcinogenesis* (1999) 20(7):1215–23. doi: 10.1093/carcin/20.7.1215
initiative. Chem Biol Interact (2009) 178(1-3):94–8. doi: 10.1016/j.cbi.2008.10.040

276. Dunistol ME, Page V, Dupont E, Pelletier G, Labrie F. Characterization, expression and immunohistochemical localization of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in human skin. J Invest Dermatol (1992) 99(4):415–21. doi: 10.1111/j.1523-1747.epi.16216131

277. Labrie F, Simard J, Luu-The V, Belanger A, Pelletier G. Structure, function and tissue-specific gene expression of 3beta-hydroxydeoxydrossterol/delta 5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues. J Steroid Biochem Mol Biol (1992) 43(8):805–26. doi: 10.1016/0960-7970(92)90308-6

278. Rheaume E, Lachance Y, Zhao HF, Breton N, Dumont M, de Launoit Y, et al. Characterization of cDNAs for human estradiol 17 beta-dehydrogenase and characterization of the gene to chromosome 17: evidence of two mRNA species orientation in the endoplasmic reticulum membrane. J Biol Chem (1999) 274(40):28762–70. doi: 10.1074/jbc.274.40.28762

279. Luu The V, Labrie C, Zhao HF, Couet J, Lachance Y, Simard J, et al. Characterization of cDNAs for human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5' termini in human placenta. Mol Endocrinol (1991) 5(8):1147–57. doi: 10.1210/mend-5-8-1147

280. Schwarz M, Wright AC, Davis DL, Nazer H, Bjorkam I, Russell DW. The bile acid synthetic gene 3beta-hydroxy-Delta 5(3)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis. J Clin Invest (2000) 106(9):1175–84. doi: 10.1172/JCI10902

281. van Grunsven EG, van Berkel E, Ijlst L, Vreken P, de Klerk JB, Adamski J, et al. Update of the LIPID MAPS comprehensive classi- cation system for lipids. J Lipid Res (2009) 50(Suppl(Suppl)):S9. doi: 10.1194/jlr.R800095-JLR200

282. Sud M, Fahy E, Cotter D, Brown A, Dennis EA, Glass CK, et al. LMSID: LIPID MAPS structure database. Nucleic Acids Res (2007) 35(Database issue):D527–32. doi: 10.1093/nar/gkj388

283. Sauter G, Fehr P, Durmuller U, Kasper M, Gudat F, et al. Localization of thromboxane synthase in human tissues by monoclonal antibody Tu 300. Virchows Arch A Pathol Anat Histopathol (1992) 421(3):249–54. doi: 10.1007/BF01611182

284. Miyata A, Hara S, Yokoyama C, Inoue H, Ullrich V, Tanabe T. Molecular cloning and expression, and immunohistochemical localization of 3 beta-hydroxysteroid dehydrogenase/delta 5-ene-4-ene isomerase in human adrenals and gonads. Mol Endocrinol (1991) 5(8):1147–57. doi: 10.1210/mend-5-8-1147

285. Clark JD, Lin LL, Kriz RW, Ramesha CS, Sultzman LA, Lin AY, et al. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell (1991) 65(6):1043–51. doi: 10.1016/0092-8674(91)90556-e

286. Cheon Y, Kim HW, Igarashi M, Modi HR, Chang L, Ma K, et al. Disturbed brain phospholipid and docosahexaenoic acid metabolism in calcium-independent phospholipase A2(2)-VIA (PLA2b)-knockout mice. Biochim Biophys Acta (2012) 1821(9):1278–86. doi: 10.1016/j.bbala.2012.02.003

287. Odermatt A, Arnold P, Stauffer A, Frey BM, Frey FJ. The N-terminal anchor associated protein (PRAP) in rat. Mol Endocrinol (1998) 12(7):1048–56. doi: 10.1210/me.1998-0452

288. Powell WS, Gravel S, Halwani F. 5-oxo-6,8,11,14-eicosatetraenoic acid is a potent stimulator of L-selectin shedding, surface expression of CD11b, actin polymerization, and calcium mobilization in human eosinophils. Am J Respir Cell Mol Biol (1999) 21(1):163–70. doi: 10.1165/rcmb.1998-0131AI

289. Hirabayashi T, Murayama T, Shimizu T. Regulatory mechanism and physiological role of cytosolic phospholipase A2. Biol Pharm Bull (2004) 27(8):1168–73. doi: 10.1248/bpb.27.1168

290. Forney J, Bass DA, Marshall LA, Seeds M, Samet JM, Chilton FH. Evidence that secretory phospholipase A2 plays a role in arachidonic acid release and eicosanoid biosynthesis by mast cells. J Immunol (1994) 152(9):4538–46.

291. van Berkel E, Ijlst L, Vreken P, de Klerk JB, Adamski J, et al. Update of the LIPID MAPS comprehensive classification system for lipids. J Lipid Res (2009) 50 Suppl(Suppl):S9. doi: 10.1194/jlr.R800095-JLR200

292. He W, Gauri M, Li T, Wang R, Lin SX. Current knowledge of the multifunctional 17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1). Gene (2016) 568(1):54–61. doi: 10.1016/j.gene.2016.04.031

293. Ziganshin AU, Zeirova JT, Zeirov A, Zhitkova J, Schneider D, Klapok J, et al. Characterization of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Eur J Biochem (1992) 200(3):1728–33. doi: 10.1173/pnas.95.5.2128

294. Nusing R, Sauter G, Fehr P, Durmuller U, Kasper M, Gudat F, et al. Localization of thromboxane synthase in human tissues by monoclonal antibody Tu 300. Virchows Arch A Pathol Anat Histopathol (1992) 421(3):249–54. doi: 10.1007/BF01611182

295. Sauter G, Fehr P, Durmuller U, Kasper M, Gudat F, et al. Localization of thromboxane synthase in human tissues by monoclonal antibody Tu 300. Virchows Arch A Pathol Anat Histopathol (1992) 421(3):249–54. doi: 10.1007/BF01611182

296. Nusing R, Sauter G, Fehr P, Durmuller U, Kasper M, Gudat F, et al. Localization of thromboxane synthase in human tissues by monoclonal antibody Tu 300. Virchows Arch A Pathol Anat Histopathol (1992) 421(3):249–54. doi: 10.1007/BF01611182

297.держиваюшего артериального кровотечения в астм. J Appl Allergy Clin Immunol (2010) 10(1):60–6. doi: 10.1097/ACI.0b013e3283349bc3
312. Capra V, Rovati GE, Mangano P, Buccellati C, Murphy RC, Sala A. Transcellular biosynthesis of eicosanoid lipid mediators. Biochim Biophys Acta (2015) 1851(4):377–82. doi: 10.1016/j.bbabio.2014.09.002
313. Chandrasekharan JA, Sharma-Walia N. Lipoxins: nature’s way to resolve inflammation. J Inflammation Res (2015) 8(1):92–9. doi: 10.1172/JIR.S90380
314. Martin TR, Pistoirese BP, Chi EY, Goodman RB, Matthay MA. Effects of leukotriene B4 in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in protein permeability. J Clin Invest (1989) 84(5):1609–19. doi: 10.1172/JCI14338
315. Feltenmark S, Gautam N, Brunnstrom A, Grif
316. Claesson HE. On the biosynthesis and biological role of eoxins and 15-
319. Pace-Asciak CR, Laneuville O, Su WG, Corey EJ, Gurevich N, Wu P, et al. A novel class of cellular glycolipids containing epoxidized arachidonate moieties. J Biol Chem (1991) 266(1):7561–9
320. Mrsny RJ, Gewirtz AT, Siccardi D, Savidge T, Hurley BP, Madara JL, et al. Human platelets generate phospholipid-esterified prostaglandins via cyclooxygenase-1 that are inhibited by low dose aspirin supplementation. J Lipid Res (2013) 54(11):3085–97. doi: 10.1194/jlr.M401533
321. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J Biol Chem (2010) 285(19):16893–903. doi: 10.1074/jbc.M109.787428
322. Brosny VA, Hammond BJ, Petruce B, et al. The rat leukocyte-type 12-lipoxygenase expresses an intrinsic hepoxilin A3 synthase activity. J Biol Chem (2004) 279(28):29023–30. doi: 10.1074/jbc.M307576200
323. Cronin A, Decker M, Arand M. Mammalian soluble epoxide hydrolase is identical to liver hepoxilin hydrolase. J Biol Chem (2011) 286(12):9668–79. doi: 10.1074/jbc.M110.188433
324. Tuckey RC, Cameron KJ. Catalytic properties of cytochrome P-450scc chain cleavage enzyme CYP11A1. J Biol Chem (2018) 293(22):8693–709. doi: 10.1074/jbc.A117.01629
325. Schoepfer GJr. Oxysterols: modulators of cholesterol metabolism and other processes. Physiol Rev (2000) 80(1):361–544. doi: 10.1152/physrev.2000.80.1.361
326. Bjorkhem I, Andersson U, Ellis E, Alvelius G, Ellergard L, Diczfalusy U, et al. From brain to bile. Evidence that conjugation and omega-hydroxylation are important for elimination of 24S-hydroxycholesterol (ceriberolsterol) in humans. J Biol Chem (2001) 276(40):37004–10. doi: 10.1074/jbc.M103828200
327. Isobe T, Nishizuka Y, Inoue Y, Watanabe H, et al. Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyicosapentaenoic acid. J Biol Chem (2012) 287(13):10525–34. doi: 10.1074/jbc.M112.406412
328. Serhan CN, Levy BD. Resolvins in inflammation: emergence of the resolving superfamily of mediators. J Clin Invest (2018) 128(7):2657–69. doi: 10.1172/JCI97943
329. Dalli J, Zhu M, Vlasenko NA, Deng B, Haegestrom JZ, Petasis NA, et al. The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J (2013) 27(7):2573–83. doi: 10.1096/fj.201227278
330. Hammond VJ, O’Donnell VB. Esterified eicosanoids: generation, characterization and function. Biochim Biophys Acta (2012) 1818(10):2243–12. doi: 10.1016/j.bbamem.2011.12.013
331. Mast BK, Hernandez-Fajardo A, Morgan AH, Stewart-Jones E, Diosozyg Y, Taylor GW, et al. Activated platelets and monocytes generate four hydroxyphosphatidylethanolamines via lipoxigenase. J Biol Chem (2007) 282(28):20515–63. doi: 10.1074/jbc.M611776200
332. Morgan LT, Thomas CP, Kuhn H, O’Donnell VB. Thrombin-activated human platelets acutely generate oxidized docosahexaenoic-acid-containing phospholipids via 12-lipoxygenase. Biochem J (2010) 431(1):141–8. doi: 10.1042/Bj20100415
333. Thomas CP, Morgan LT,马克, Murphy RC, Kuhn H, Hazen SL, et al. Phospholipid-esterified eicosanoids are generated in agonist-activated human platelets and enhance tissue factor-dependent thrombin generation. J Biol Chem (2010) 285(19):16893–903. doi: 10.1074/jbc.M109.787428
334. Aldrovandi M, Hammond BJ, Podmore H, Hornshaw M, Clark SR, Marnett LJ, et al. Human platelets generate phospholipid-esterified prostaglandins via cyclooxygenase-1 that are inhibited by low dose aspirin supplementation. J Biol Chem (2013) 54(11):3085–97. doi: 10.1194/jlr.M401533
335. Karara A, Dishman E, Falck JR, Capdevila JH. Endogenous epoxyeicosatrienoyl-phospholipids. A novel class of cellular glycolipids containing epoxidized arachidonate moieties. J Biol Chem (1991) 266(1):7561–9
336. O’Donnell VB, Aldrovandi M, Murphy RC, Kroneke G. Enzymatically oxidized phospholipids assume center stage as essential regulators of innate immunity and cell death. Sci Signaling (2012) 19(527):eaau2293. doi: 10.1126/scisignal.aau2293
337. Morgan AH, Diosozyg Y, Mark, Thomas CP, Clark SR, Mathie SA, et al. Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation-dependent formation in Th-2 disease. J Biol Chem (2009) 284(32):21185–91. doi: 10.1074/jbc.M109.021634
338. Liu GY, Moon SH, Jenkins CM, Sims HF, Guan S, Gross RW. Synthesis of oxidized phospholipids by sn-1 acyltransferase using 2-15-HETE lysophospholipids. J Biol Chem (2019) 294(26):10456–9. doi: 10.1074/jbc.RA119.008766
339. Jenkins CM, Yang K, Liu G, Moon SH, Dilthey BG, Gross RW. Cytochrome c oxidase is an oxidative stress-activated plasmalogenase that cleaves plasmenylcholine and plasmenylethanolamine at the sn-1 vinyl ether linkage. J Biol Chem (2018) 293(22):8693–709. doi: 10.1074/jbc.A117.01629
340. Tuckey RC, Cameron KJ. Catalytic properties of cytochrome P-450sc purifying from the human placenta: comparison to bovine cytochrome P-450sc. Biochim Biophys Acta (1993) 1163(2):185–94. doi: 10.1016/0005-2716(93)90180-y
341. Mast N, Annalora AJ, Lodowski DT, Palczewski K, Stout CD, Pikuleva I. Structural basis for three-step sequential catalysis by the cholesterol side chain cleavage enzyme CYP11A1. J Biol Chem (2011) 286(7):5607–13. doi: 10.1074/jbc.M110.188433
342. Lund EG, Kerr TA, Sakai J, Li WP, Russell DW. cDNA cloning of mouse and human Toll-like receptor activation suppresses immunoglobulin A production. Nature (2019) 598(7920):593–9. doi: 10.1016/j.nature.2019.09.012
343. Brown JC, Bitmansour AD, McDonald JG, Thompson BM, Liang G, Russell DW. 25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production. Proc Natl Acad Sci U S A (2009) 106(39):16764–9. doi: 10.1073/pnas.0909142106
Biosynthesis of Oxidized Lipids

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Hajeyah, Griffths, Wang, Finch and O'Donnell. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.